



Cochrane
Library

Cochrane Database of Systematic Reviews

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (Review)

Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettioli S

Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettioli S.
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.
Cochrane Database of Systematic Reviews 2015, Issue 11. Art. No.: CD009464.
DOI: [10.1002/14651858.CD009464.pub2](https://doi.org/10.1002/14651858.CD009464.pub2).

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	4
BACKGROUND	9
OBJECTIVES	10
METHODS	10
RESULTS	12
Figure 1.	13
Figure 2.	14
Figure 3.	15
DISCUSSION	19
AUTHORS' CONCLUSIONS	20
ACKNOWLEDGEMENTS	21
REFERENCES	22
CHARACTERISTICS OF STUDIES	30
DATA AND ANALYSES	57
Analysis 1.1. Comparison 1 Cannabinoid versus placebo, Outcome 1 Absence of nausea.	58
Analysis 1.2. Comparison 1 Cannabinoid versus placebo, Outcome 2 Absence of vomiting.	58
Analysis 1.3. Comparison 1 Cannabinoid versus placebo, Outcome 3 Absence of nausea and vomiting.	59
Analysis 1.4. Comparison 1 Cannabinoid versus placebo, Outcome 4 Depression.	59
Analysis 1.5. Comparison 1 Cannabinoid versus placebo, Outcome 5 Dysphoria.	59
Analysis 1.6. Comparison 1 Cannabinoid versus placebo, Outcome 6 'Feeling high'.	60
Analysis 1.7. Comparison 1 Cannabinoid versus placebo, Outcome 7 Paranoia.	60
Analysis 1.8. Comparison 1 Cannabinoid versus placebo, Outcome 8 Sedation.	60
Analysis 1.9. Comparison 1 Cannabinoid versus placebo, Outcome 9 Participant preference.	60
Analysis 1.10. Comparison 1 Cannabinoid versus placebo, Outcome 10 Withdrawal for any reason.	61
Analysis 1.11. Comparison 1 Cannabinoid versus placebo, Outcome 11 Withdrawal due to adverse event.	61
Analysis 1.12. Comparison 1 Cannabinoid versus placebo, Outcome 12 Withdrawal due to lack of efficacy.	61
Analysis 2.1. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 1 Absence of nausea.	64
Analysis 2.2. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 2 Absence of nausea (subgroup analysis 2).	64
Analysis 2.3. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 3 Absence of vomiting.	65
Analysis 2.4. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 4 Absence of vomiting (subgroup analysis 2).	65
Analysis 2.5. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 5 Absence of nausea and vomiting.	66
Analysis 2.6. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 6 Absence of nausea and vomiting (subgroup analysis 1).	66
Analysis 2.7. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 7 Absence of nausea and vomiting (subgroup analysis 2).	67
Analysis 2.8. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 8 Dizziness.	67
Analysis 2.9. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 9 Dysphoria.	68
Analysis 2.10. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 10 Euphoria.	68
Analysis 2.11. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 11 'Feeling high'.	69
Analysis 2.12. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 12 Hallucinations.	69
Analysis 2.13. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 13 Postural hypotension.	70
Analysis 2.14. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 14 Paranoia.	71
Analysis 2.15. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 15 Sedation.	71
Analysis 2.16. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 16 Depression.	72
Analysis 2.17. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 17 Participant preference.	72
Analysis 2.18. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 18 Withdrawal for any reason.	73
Analysis 2.19. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 19 Withdrawal due to adverse event.	73
Analysis 2.20. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 20 Withdrawal due to lack of efficacy.	74

Analysis 3.1. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 1 Absence of nausea.	75
Analysis 3.2. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 2 Absence of vomiting.	75
Analysis 3.3. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 3 Absence of nausea and vomiting.	76
Analysis 3.4. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 4 Depression.	76
Analysis 3.5. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 5 Dizziness.	76
Analysis 3.6. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 6 Dysphoria.	76
Analysis 3.7. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 7 Paranoia.	76
Analysis 3.8. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 8 Sedation.	77
Analysis 3.9. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 9 Withdrawal for any reason.	77
Analysis 3.10. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 10 Withdrawal due to adverse event.	77
Analysis 3.11. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 11 Withdrawal due to lack of efficacy.	77
APPENDICES	77
CONTRIBUTIONS OF AUTHORS	80
DECLARATIONS OF INTEREST	80
SOURCES OF SUPPORT	80
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	80
INDEX TERMS	81

[Intervention Review]

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy

Lesley A Smith¹, Fredric Azariah², Verna TC Lavender³, Nicola S Stoner⁴, Silvana Bettiol⁵

¹Department of Psychology, Social Work and Public Health, Oxford Brookes University, Oxford, UK. ²School of Health and Social Care, Oxford Brookes University, Oxford, UK. ³Department of Clinical Health Care, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK. ⁴Pharmacy, Oxford University Hospitals NHS Trust, Oxford, UK. ⁵Department of Medicine and Paramedicine, Faculty of Health, University of Tasmania, Hobart, Australia

Contact address: Lesley A Smith, Department of Psychology, Social Work and Public Health, Oxford Brookes University, Jack Straws Lane, Marston, Oxford, OX3 0FL, UK. lesleysmith@brookes.ac.uk.

Editorial group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Publication status and date: New, published in Issue 11, 2015.

Citation: Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. *Cochrane Database of Systematic Reviews* 2015, Issue 11. Art. No.: CD009464. DOI: [10.1002/14651858.CD009464.pub2](https://doi.org/10.1002/14651858.CD009464.pub2).

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Cannabis has a long history of medicinal use. Cannabis-based medications (cannabinoids) are based on its active element, delta-9-tetrahydrocannabinol (THC), and have been approved for medical purposes. Cannabinoids may be a useful therapeutic option for people with chemotherapy-induced nausea and vomiting that respond poorly to commonly used anti-emetic agents (anti-sickness drugs). However, unpleasant adverse effects may limit their widespread use.

Objectives

To evaluate the effectiveness and tolerability of cannabis-based medications for chemotherapy-induced nausea and vomiting in adults with cancer.

Search methods

We identified studies by searching the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO and LILACS from inception to January 2015. We also searched reference lists of reviews and included studies. We did not restrict the search by language of publication.

Selection criteria

We included randomised controlled trials (RCTs) that compared a cannabis-based medication with either placebo or with a conventional anti-emetic in adults receiving chemotherapy.

Data collection and analysis

At least two review authors independently conducted eligibility and risk of bias assessment, and extracted data. We grouped studies based on control groups for meta-analyses conducted using random effects. We expressed efficacy and tolerability outcomes as risk ratio (RR) with 95% confidence intervals (CI).

Main results

We included 23 RCTs. Most were of cross-over design, on adults undergoing a variety of chemotherapeutic regimens ranging from moderate to high emetic potential for a variety of cancers. The majority of the studies were at risk of bias due to either lack of allocation con-

cealment or attrition. Trials were conducted between 1975 and 1991. No trials involved comparison with newer anti-emetic drugs such as ondansetron.

Comparison with placebo

People had more chance of reporting complete absence of vomiting (3 trials; 168 participants; RR 5.7; 95% CI 2.6 to 12.6; low quality evidence) and complete absence of nausea and vomiting (3 trials; 288 participants; RR 2.9; 95% CI 1.8 to 4.7; moderate quality evidence) when they received cannabinoids compared with placebo. The percentage of variability in effect estimates that was due to heterogeneity rather than chance was not important ($I^2 = 0\%$ in both analyses).

People had more chance of withdrawing due to an adverse event (2 trials; 276 participants; RR 6.9; 95% CI 1.96 to 24; $I^2 = 0\%$; very low quality evidence) and less chance of withdrawing due to lack of efficacy when they received cannabinoids, compared with placebo (1 trial; 228 participants; RR 0.05; 95% CI 0.0 to 0.89; low quality evidence). In addition, people had more chance of 'feeling high' when they received cannabinoids compared with placebo (3 trials; 137 participants; RR 31; 95% CI 6.4 to 152; $I^2 = 0\%$).

People reported a preference for cannabinoids rather than placebo (2 trials; 256 participants; RR 4.8; 95% CI 1.7 to 13; low quality evidence).

Comparison with other anti-emetics

There was no evidence of a difference between cannabinoids and prochlorperazine in the proportion of participants reporting no nausea (5 trials; 258 participants; RR 1.5; 95% CI 0.67 to 3.2; $I^2 = 63\%$; low quality evidence), no vomiting (4 trials; 209 participants; RR 1.11; 95% CI 0.86 to 1.44; $I^2 = 0\%$; moderate quality evidence), or complete absence of nausea and vomiting (4 trials; 414 participants; RR 2.0; 95% CI 0.74 to 5.4; $I^2 = 60\%$; low quality evidence). Sensitivity analysis where the two parallel group trials were pooled after removal of the five cross-over trials showed no difference (RR 1.1; 95% CI 0.70 to 1.7) with no heterogeneity ($I^2 = 0\%$).

People had more chance of withdrawing due to an adverse event (5 trials; 664 participants; RR 3.9; 95% CI 1.3 to 12; $I^2 = 17\%$; low quality evidence), due to lack of efficacy (1 trial; 42 participants; RR 3.5; 95% CI 1.4 to 8.9; very low quality evidence) and for any reason (1 trial; 42 participants; RR 3.5; 95% CI 1.4 to 8.9; low quality evidence) when they received cannabinoids compared with prochlorperazine.

People had more chance of reporting dizziness (7 trials; 675 participants; RR 2.4; 95% CI 1.8 to 3.1; $I^2 = 12\%$), dysphoria (3 trials; 192 participants; RR 7.2; 95% CI 1.3 to 39; $I^2 = 0\%$), euphoria (2 trials; 280 participants; RR 18; 95% CI 2.4 to 133; $I^2 = 0\%$), 'feeling high' (4 trials; 389 participants; RR 6.2; 95% CI 3.5 to 11; $I^2 = 0\%$) and sedation (8 trials; 947 participants; RR 1.4; 95% CI 1.2 to 1.8; $I^2 = 31\%$), with significantly more participants reporting the incidence of these adverse events with cannabinoids compared with prochlorperazine.

People reported a preference for cannabinoids rather than prochlorperazine (7 trials; 695 participants; RR 3.3; 95% CI 2.2 to 4.8; $I^2 = 51\%$; low quality evidence).

In comparisons with metoclopramide, domperidone and chlorpromazine, there was weaker evidence, based on fewer trials and participants, for higher incidence of dizziness with cannabinoids.

Two trials with 141 participants compared an anti-emetic drug alone with a cannabinoid added to the anti-emetic drug. There was no evidence of differences between groups; however, the majority of the analyses were based on one small trial with few events.

Quality of the evidence

The trials were generally at low to moderate risk of bias in terms of how they were designed and do not reflect current chemotherapy and anti-emetic treatment regimens. Furthermore, the quality of evidence arising from meta-analyses was graded as low for the majority of the outcomes analysed, indicating that we are not very confident in our ability to say how well the medications worked. Further research is likely to have an important impact on the results.

Authors' conclusions

Cannabis-based medications may be useful for treating refractory chemotherapy-induced nausea and vomiting. However, methodological limitations of the trials limit our conclusions and further research reflecting current chemotherapy regimens and newer anti-emetic drugs is likely to modify these conclusions.

PLAIN LANGUAGE SUMMARY

Cannabis-based medicine for nausea and vomiting in people treated with chemotherapy for cancer

Background

As many as three-quarters of people who receive chemotherapy experience nausea (feeling sick) and vomiting (being sick), which many find distressing. While conventional anti-sickness medicines are effective, they do not work for everyone, all of the time. Therapeutic drugs based on the active ingredient of cannabis, known as THC (delta-9-tetrahydrocannabinol), have been approved for use as anti-sickness medicines in some countries.

Review question

Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

This review evaluated how well cannabis-based medicines work for treating nausea and vomiting due to chemotherapy treatment in people with cancer, and what the side effects were.

Main findings

This review of 23 randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) found that fewer people who received cannabis-based medicines experienced nausea and vomiting than people who received placebo (a pretend medicine). The proportion of people who experienced nausea and vomiting who received cannabis-based medicines was similar to conventional anti-nausea medicines. However, more people experienced side effects such as 'feeling high', dizziness, sedation (feeling relaxed or sleepy) and dysphoria (feeling uneasy or dissatisfied) and left the study due to the side effects with cannabis-based medicines, compared with either placebo or other anti-nausea medicines. In trials where people received cannabis-based medicines and conventional medicines in turn, overall people preferred the cannabis-based medicines.

Quality of the evidence

The trials were of generally of low to moderate quality and reflected chemotherapy treatments and anti-sickness medicines that were around in the 1980s and 1990s. Also, the results from combining studies on the whole were of low quality. This means that we are not very confident in our ability to say how well the anti-sickness medicines worked, and further research reflecting modern treatment approaches is likely to have an important impact on the results.

Cannabis-based medicines may be useful for treating chemotherapy-induced nausea and vomiting that responds poorly to commonly used anti-sickness medicines.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. Cannabinoids compared with placebo for chemotherapy-induced nausea and vomiting

Cannabinoids compared with placebo for chemotherapy-induced nausea and vomiting

Patient or population: people with chemotherapy-induced nausea and vomiting

Intervention: cannabinoids

Comparison: placebo

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Placebo	Cannabinoids				
Absence of nausea (follow-up)	3 per 100	6 per 100 (1 to 63)	RR 2.0 (0.2 to 21)	96 (2)	⊕⊕○○ low ^{3,5}	RR > 1 indicates treatment favours cannabinoids
Absence of vomiting (follow-up)	6 per 100	34 per 100 (16 to 76)	RR 5.7 (2.6 to 12.6)	168 (3)	⊕⊕○○ low ^{3,5}	RR > 1 indicates treatment favours cannabinoids
Absence of nausea and vomiting (follow-up)	11 per 100	32 per 100 (20 to 52)	RR 2.9 (1.8 to 4.7)	288 (3)	⊕⊕⊕○ moderate ³	RR > 1 indicates treatment favours cannabinoids
Participant preference (follow-up)	Low-risk value ²		RR 4.8 (1.7 to 13)	256 (2)	⊕⊕○○ low ^{3,4}	RR > 1 indicates treatment favours cannabinoids
	8 per 100	38 per 100 (14 to 104)				
	High-risk value ²					
	22 per 100	106 (37 to 286)				
Withdrawal any reason	10 per 1000	3 per 1000	RR 0.31 (0.01 to 7)	33 (1)	⊕○○○ very low ^{1,3,5}	RR < 1 indicates treatment favours cannabinoids

(follow-up)		(0.1 to 7)				
Withdrawal due to adverse event	80 per 1000	4 per 1000	RR 6.9 (1.96 to 24)	276 (2)	⊕⊕⊕⊕	RR < 1 indicates treatment favours cannabinoids
(follow-up)		(0.0 to 72)			very low ^{1,3,5}	

*The **assumed risk** for all outcomes is the median control group risk across studies. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **RR:** risk ratio.

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹ Sparse data.

² The low- and high-risk values are the two extreme proportions of people with a preference for one drug over another.

³ Limitations in the design (cross-over study) and high attrition.

⁴ Unexplained heterogeneity.

⁵ Imprecision.

Summary of findings 2. Cannabinoids compared with other anti-emetic agent for chemotherapy-induced nausea and vomiting

Cannabinoids compared with other anti-emetic agent for chemotherapy-induced nausea and vomiting

Patient or population: people with chemotherapy-induced nausea and vomiting

Intervention: cannabinoids

Comparison: other anti-emetic agent

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Other anti-emetic agent	Cannabinoids				
Absence of nausea (follow-up)	37 per 100	56 per 100 (25 to 118)	RR 1.46 (0.67 to 3.15)	258 (5)	⊕⊕⊕⊕ low ^{3,4}	RR > 1 indicates treatment

						ment favours cannabinoids
Absence of vomiting (follow-up)	Low-risk value ²		RR 1.1 (0.86 to 1.4)	209 (4)	⊕⊕⊕⊖ moderate ³	RR > 1 indicates treatment favours cannabinoids
	10 per 1 000	11 per 1 000 (9 to 14)				
	High-risk value ²					
	70 per 100	77 per 100 (60 to 98)				
Absence of nausea and vomiting (follow-up)	Low-risk value ²		RR 2.0 (0.74 to 5.4)	414 (4)	⊕⊕⊖⊖ low ^{3,4}	RR > 1 indicates treatment favours cannabinoids
	1 per 100	2 per 100 (1 to 5)				
	High-risk value ²					
	42 per 100	84 per 100 (31 to 227)				
Participant preference (follow-up)	23 per 100	64 per 100 (44 to 92)	RR 2.8 (1.9 to 4.0)	799 (9)	⊕⊕⊖⊖ low ^{3,4}	RR > 1 indicates treatment favours cannabinoids
Withdrawal any reason (follow-up)	19 per 100	67 per 100 (27 to 171)	RR 3.5 (1.4 to 9.0)	42 (1)	⊕⊕⊖⊖ low ^{1,3}	RR < 1 indicates treatment favours cannabinoids
Withdrawal due to lack of efficacy (follow-up)	20 per 100	19 per 100 (1 to 420)	RR 0.97 (0.04 to 21)	118 (2)	⊕⊖⊖⊖ very low ^{1,3,4}	RR < 1 indicates treatment favours cannabinoids
Withdrawal due to adverse event (follow-up)	3 per 100	10 per 100 (4 to 24)	RR 3.2 (1.3 to 8.0)	740 (6)	⊕⊕⊖⊖ low ^{3,5}	RR < 1 indicates treat-



ment favours
cannabinoids

*The **assumed risk** for all outcomes is the median control group risk across studies. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **RR:** risk ratio.

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹ Sparse data.

² The low- and high-risk values are the two extreme proportions of people with a preference for one drug over another.

³ Limitations in the design (cross-over study) and high attrition.

⁴ Unexplained heterogeneity.

⁵ Imprecision.

Summary of findings 3. Cannabinoid plus other anti-emetic agent compared with other anti-emetic monotherapy for chemotherapy-induced nausea and vomiting

Cannabinoid plus other anti-emetic agent compared with other anti-emetic monotherapy for chemotherapy-induced nausea and vomiting

Patient or population: people with chemotherapy-induced nausea and vomiting

Intervention: cannabinoid plus other anti-emetic agent

Comparison: anti-emetic monotherapy

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Anti-emetic monotherapy	Cannabinoid plus other anti-emetic agent				
Absence of nausea (follow-up)	1 per 100	10 per 100 (0 to 183)	RR 10 (0.61 to 183)	37 (1)	⊕⊕⊕⊕ very low ^{1,2,3}	RR > 1 indicates treatment favours cannabinoids
Absence of vomiting	29 per 100	44 per 100	RR 1.5 (0.69 to 3.1)	89 (2)	⊕⊕⊕⊕ low ^{1,2}	RR > 1 indicates treatment favours cannabinoids

(follow-up)		(20 to 90)				
Absence of nausea and vomiting	30 per 100	48 per 100 (20 to 108)	RR 1.6 (0.68 to 3.6)	37 (1)	⊕⊕○○ low^{1,2}	RR > 1 indicates treatment favours cannabinoids
(follow-up)						
Withdrawal any reason	20 per 100	26 per 100 (8 to 84)	RR 1.3 (0.41 to 4.2)	41 (1)	⊕⊕○○ low^{1,2}	RR < 1 indicates treatment favours cannabinoids
(follow-up)						
Withdrawal due to adverse event	1 per 100	7 per 100 (1 to 55)	RR 7.0 (0.88 to 55)	105 (2)	⊕○○○ very low^{1,2,3}	RR < 1 indicates treatment favours cannabinoids
(follow-up)						
Withdrawal due to lack of efficacy	20 per 100	2 per 100 (0 to 40)	RR 0.12 (0.01 to 2.0)	41 (1)	⊕⊕○○ low^{1,2}	RR < 1 indicates treatment favours cannabinoids
(follow-up)						

*The **assumed risk** for all outcomes is the median control group risk across studies. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **RR:** risk ratio.

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹ Sparse data.

² Limitations in the design (cross-over study) and high attrition.

³ Imprecision.

BACKGROUND

Description of the condition

Nausea and vomiting are considered the most stressful adverse effects of chemotherapy by people with cancer (Barowski 1984; de Boer-Dennert 1997; Russo 2014). Up to 75% of all people with cancer experience chemotherapy-related nausea and vomiting (Schwartzberg 2007), which can lead to depression, anxiety and a feeling of helplessness, lower quality of life and may affect chemotherapy adherence (Dodds 1985; Janelins 2013; Wilcox 1982).

Guidelines that inform standard protocols and algorithms ensure best practice in managing chemotherapy-induced nausea and vomiting (Basch 2011; NCCN 2014; Roila 2010). However, standardised care and clinical decision-making occurs within the context of individualised care, where focus on a person's preference is key to reducing chemotherapy-related stress in people with cancer. People's preference for cancer treatment is illustrated by several studies that report people's preferences for specific chemotherapy regimens based on quality of life (reduced treatment toxicity), rather than treatment efficacy (increased predicted survival) (Beusterien 2014; Dubey 2005; Kuchuk 2013; Sun 2002). Therefore, it is important to consider use of all approved anti-emetics that treat chemotherapy-induced nausea and vomiting, where people may have a preference for one or another type of treatment.

During the 1990s, serotonin (5-HT₃) receptor antagonists, combined with dexamethasone, became the gold standard in the prevention of vomiting caused by chemotherapy (Gralla 1999; MASCC 1998). Episodes of chemotherapy-induced nausea and vomiting are classified by distinct clinical phases: acute - within the first 24 hours of treatment; delayed - following the first 24 hours of treatment and anticipatory - a learned response where refractory nausea and vomiting have been experienced during previous chemotherapy cycles, which results in nausea and vomiting prior to a subsequent treatment cycle (Roila 2010). Nowadays, the anti-emetics indicated for chemotherapy with high emesis-inducing potential are 5-HT₃ receptor antagonists, dexamethasone and aprepitant given during the acute emetic phase (Basch 2011; Gralla 2013; NCCN 2014; Olver 2004). However, if there is failure to respond, or there is an increase in vomiting, this cannot be corrected by increasing the dose or frequency of administration of the prophylactic anti-emetics (5-HT₃ receptor antagonists, dexamethasone and aprepitant). People who experience refractory nausea and vomiting (i.e. people who do not respond to first-line prophylactic anti-emetics) can have additional anti-emetics added to their existing prophylactic anti-emetic regimen, such as a dopamine antagonist (metoclopramide, domperidone), a phenothiazine (prochlorperazine or levomepromazine), an antihistamine (cyclizine) or a butyrophenone (haloperidol) anti-emetic (Gralla 1999; Gralla 2013). Benzodiazepines (lorazepam) can also be added to the prophylactic anti-emetic regimen for refractory people, particularly those who are anxious or experience anticipatory nausea and vomiting (Gralla 1999). Dexamethasone is one of the most effective anti-emetics for delayed nausea and vomiting, so people experiencing delayed refractory emesis can be prescribed an extended course of dexamethasone on a reducing dosage (Gralla 1999; Huang 2004; Ioannidis 2000). More recently, there have been reports of olanzapine being an effective adjunctive treatment for refractory nausea and vomiting (Gralla 2013). A second-generation 5HT₃ receptor antagonist, palonosetron, is effective in refrac-

tory nausea and vomiting to substitute for a first-generation 5HT₃ receptor antagonist (Gralla 2013). In addition, if people are unable to tolerate oral 5HT₃ receptor antagonists, other formulations can be considered such as a 24-hour granisetron transdermal patch, an orally disintegrating ondansetron melt, or ondansetron oral film (Gralla 2013). Consideration should also be made for other formulations of adjunctive anti-emetics, such as buccal or rectal formulations (Gralla 2013).

According to Walsh 2003, cannabinoids, the active agents derived from cannabis (marijuana), may be considered for controlling nausea and vomiting as fourth-line agents. They have been recommended in international anti-emetic guidelines for the prevention of chemotherapy-induced nausea and vomiting (Gralla 1999). Cannabinoids are thought to work through different mechanisms to other agents given for nausea and vomiting (see: [How the intervention might work](#)) and may be effective in people with cancer who respond poorly to commonly used agents (Machado Rocha 2008).

Description of the intervention

Cannabis has been used for medicinal purposes throughout history (Karniol 2001). It was listed on the American pharmacopoeia until 1944 (Bonnie 1974), when it was removed due to political pressure and was banned in the USA (Walsh 2003). Although cannabis has not been re-listed on the American pharmacopoeia, in 1986 the Food and Drug Administration (FDA) authorised the use of its active element, delta-9-tetrahydrocannabinol (delta-9-THC), for medical purposes (Walsh 2003), to treat the adverse effects of nausea and vomiting in people with cancer receiving chemotherapy (Gralla 1999).

Currently, there are two synthetic delta-9-THC (cannabinoid) agents that have been evaluated in clinical trials that are approved for the treatment of nausea and vomiting in people with cancer treated with chemotherapy. These are oral formulations of trans(+)-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one, nabilone, and (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, dronabinol.

How the intervention might work

Cannabinoids affect the user by interacting with various receptors in different areas of the brain (Grotenhermen 2002). To date, two types of cannabinoid receptors have been identified, termed CB₁ and CB₂. Two substances naturally occurring in the brain that bind to and activate CB₁ receptors are anandamide (Devane 1992) and 2-arachidonoylglycerol (2-AG) (Mechoulam 1995; Sugiura 1995). The cannabinoid receptors, and other naturally occurring substances that bind to them, are collectively termed the 'endocannabinoid system' (Rodríguez de Fonseca 2005). The blockage of CB₁ cannabinoid receptors induces vomiting, suggesting the existence of cannabinoid receptors within the areas of the brain related to nausea and vomiting. This also suggests that the delta-9-THC anti-emetic activity may be due to stimulation of the CB₁ receptor (Darmani 2001).

Why it is important to do this review

A systematic review of randomised controlled trials (RCTs) published up to the year 2000 concluded that cannabinoids may be

useful for controlling chemotherapy-induced nausea and vomiting, but that harmful adverse effects may limit their widespread use (Tramer 2001). This meta-analysis pooled placebo-controlled and active controlled trials together. Furthermore, a more recently published systematic review came to a similar conclusion regarding effectiveness, but did not report on the adverse effects (Machado Rocha 2008). Cannabinoids are currently rarely used in clinical practice, and the publication of a systematic review of cannabinoids in highly emetic chemotherapy will provide an evidence base for their use in people with refractory nausea and vomiting.

OBJECTIVES

To evaluate the effectiveness and tolerability of cannabis-based medications for chemotherapy-induced nausea and vomiting in adults with cancer.

METHODS

Criteria for considering studies for this review

Types of studies

RCTs of cross-over or parallel group design with active or placebo control groups, or both.

Types of participants

Adults aged 18 years and over presenting with any type of cancer and receiving chemotherapeutic treatment, independent of gender and clinical setting. The chemotherapeutic regimens include drugs with low, moderate or high emetic potential.

We excluded children and young people aged under 18 years, since prevention and treatment of chemotherapy-induced nausea and vomiting, including use of cannabinoids, has been reported in this population in another Cochrane Review (Phillips 2010).

For the purpose of this review, chemotherapeutic treatments were those containing cytotoxic systemic anti-cancer treatments.

Two review authors (VL and NS) independently classified chemotherapeutic regimens, containing one or more chemotherapy agents as low, moderate, moderate to high, or high emetic potential using both American Society of Clinical Oncology (ASCO) guidelines (Basch 2011) and MASCC (Multinational Association of Supportive Care in Cancer)/European Society for Medical Oncology (ESMO) guidelines (Roila 2010). We resolved differences in assessment by discussion.

Types of interventions

Experimental arm: licensed pharmacological interventions based on cannabinoids derived from cannabis: nabilone and dronabinol used either as monotherapy or adjunct to conventional dopamine antagonists.

Control arm: placebo or conventional dopamine antagonists.

Types of outcome measures

Primary outcomes

- Complete control of nausea and vomiting (absence of episodes of nausea and vomiting without use of rescue medication) in the acute phase (within 24 hours of treatment with chemother-

apy) and in the delayed phase (after 24 hours' treatment with chemotherapy) of nausea and vomiting.

- Complete control of vomiting (absence of episodes of vomiting without use of rescue medication) in the acute and delayed phases of nausea and vomiting.
- Complete control of nausea (absence of episodes of nausea without use of rescue medication) in the acute and delayed phases of nausea and vomiting.

Secondary outcomes

- Withdrawal due to adverse effects of anti-emetic.
- Withdrawal due to any anti-emetic-related reason.
- Withdrawal due to lack of anti-emetic efficacy.
- Cross-over studies only: participant preference for one or other of the interventions (cannabis or control).
- Incidence of particular adverse effects: 'feeling high', sedation, euphoria, dizziness, heightened sense of anxiety or agitation (dysphoria), depression, hallucinations, paranoia, hypotension, focal dystonia, extrapyramidal effects and oculogyric crisis.

Search methods for identification of studies

We sought papers in all languages and carried out translations wherever necessary.

Electronic searches

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (*The Cochrane Library*, 2015, Issue 1), MEDLINE accessed via Ovid (from 1966 to January week 3 2015), EMBASE accessed via Ovid (from 1980 to January week 3 2015), PsycINFO accessed via Ovid (from inception to January week 2 2015) and LILACS (from inception to January 2015). Appendix 1, Appendix 2, Appendix 3, Appendix 4, and Appendix 5 show the search strategies.

All relevant articles were identified on PubMed and, using the 'related articles' feature, we carried out a further search for newly published articles.

Searching other resources

Unpublished and grey literature

We searched metaRegister (www.controlled-trials.com/rct), Physicians Data Query (www.nci.nih.gov), www.clinicaltrials.gov, and www.cancer.gov/clinicaltrials for ongoing trials. We searched for conference proceedings and abstracts through ZETOC (zetoc.mimas.ac.uk) and WorldCat Dissertations.

Handsearching

We examined bibliographical references of all the relevant studies in detail in order to find studies not identified in the electronic search, and handsearched key textbooks and previous systematic reviews and reports of conferences (i.e. ESMO and ASCO).

Data collection and analysis

Selection of studies

We downloaded all the titles and abstracts retrieved by electronic searching to a reference management database; we removed duplicates and three review authors (LS, FA, SB) independently examined the remaining references. We excluded those studies that clearly did not meet the inclusion criteria and we obtained copies

of the full text of potentially relevant references. Three review authors (LS, FA, SB) independently assessed the eligibility of the retrieved papers. The review authors were not blinded to the authors' names, institutions and journals of publication. We resolved disagreements by discussion and documented the reasons for exclusion in the [Characteristics of excluded studies](#) table.

Data extraction and management

For the included studies, two review authors (FA, LS) independently abstracted data on characteristics of study participants (inclusion criteria, age, gender, type of cancer and stage of disease, co-morbidities, co-interventions and chemotherapy regimens); dose, frequency, route of administration and duration of experimental and control interventions; risk of bias (see [Assessment of risk of bias in included studies](#)); outcomes (see [Types of outcome measures](#)) and deviations from the protocol onto a data abstraction form specially designed for the review and checked by a third author (SB). We resolved disagreements by discussion or by appeal.

For dichotomous outcomes (such as number of people with chemotherapy-induced nausea and vomiting per treatment group that did not present with symptoms of nausea and vomiting, described as absence of episodes of nausea and vomiting, to the end of the period of study; or withdrawals), we extracted the number of participants in each treatment arm who experienced the outcome of interest and the number of participants assessed in order to estimate a risk ratio (RR).

Wherever possible, all data extracted were those relevant to an intention-to-treat analysis, in which participants were analysed in the groups to which they were assigned. For cross-over studies, we extracted information on the number of cross-over periods, duration of washout periods and whether a paired design had been taken into consideration in the analysis.

We notes the time points at which outcomes were collected and reported.

Unit of analysis

For cross-over studies, we extracted the number of events as the numerator and the number analysed as the denominator for each treatment period.

Assessment of risk of bias in included studies

We assessed the risk of bias in included RCTs using the Cochrane's 'Risk of bias' tool ([Higgins 2011](#)). This included assessment of:

- method used for generating the randomisation sequence allocation of participants to the treatment arms;
- allocation concealment;
- blinding (of participants, healthcare providers and outcome assessors);
- reporting of incomplete outcome data (studies were considered at high risk of bias if more than 80% of people were assessed for primary outcomes): proportion of losses to follow-up and association with treatment arms, reasons for drop-out and association of drop-outs with treatment arms;
- selective reporting of outcomes;
- any other sources of bias that were pre-defined as carry-over effects and unbiased data available for analysis for cross-over trials.

Three review authors independently applied the 'Risk of bias' tool and resolved differences by discussion. We summarised results in both a 'Risk of bias' graph and a 'Risk of bias' summary. We interpreted results of meta-analyses in light of the findings with respect to risk of bias.

Measures of treatment effect

For dichotomous outcomes, we calculated the RR and its respective 95% confidence interval (CI). We incorporated cross-over trials in the meta-analyses using reported summary effect estimates. Where the carry-over effects were evident for a particular study, then we only used the data for the first period for the meta-analysis.

Dealing with missing data

We did not impute missing outcome data for any of the outcomes. If contact details could be obtained, we contacted trial authors and requested missing data.

Assessment of heterogeneity

We assessed the heterogeneity between the trials by visual inspection of forest plots, by estimation of the percentage heterogeneity between trials that could not be ascribed to sampling variation ([Higgins 2003](#)), and by a formal statistical test of the significance of the heterogeneity ([Deeks 2001](#)). We interpreted the I^2 value according to recommendations in the *Cochrane Handbook for Systematic Reviews of Interventions* as follows ([Higgins 2011](#)):

- 0% to 40%: might not be important;
- 30% to 60%: may represent moderate heterogeneity;
- 50% to 90%: may represent substantial heterogeneity;
- 75% to 100%: considerable heterogeneity.

Where there was evidence of substantial heterogeneity, we investigated and reported the possible reasons for this.

Assessment of reporting biases

We examined funnel plots corresponding to meta-analysis of the primary outcome if there were at least 10 trials included in the meta-analysis to assess the potential for small-study effects such as publication bias.

Data synthesis

Where we judged the trials sufficiently similar, we pooled their results in a meta-analysis. For dichotomous outcomes, we combined the RR for each study. We used random-effects models with inverse variance weighting for all meta-analyses due to the clinical and methodological diversity of the studies (see [Characteristics of included studies](#) table).

If trials had multiple treatment groups, we divided the 'shared' comparison group into the number of treatment groups and treated comparisons between each treatment group and the split comparison group as independent comparisons.

Subgroup analysis and investigation of heterogeneity

We conducted the following subgroup analyses for the primary outcome if sufficient trials were available:

- history of cannabis use, naive users versus prior users of cannabis;

- history of exposure to chemotherapy, chemotherapy naive versus prior chemotherapy treatment;
- type of cannabinoid agent, nabilone versus dronabinol.

Sensitivity analysis

We carried out sensitivity analyses for the primary outcome, if sufficient trials were available, excluding trials at high risk of bias and trials of a cross-over design. We also analysed the influence of the following factors on estimates of treatment effect:

- repeating the analysis excluding trials where chemotherapeutic regimens had low or low-moderate emetic potential, or the emetic potential was unclassifiable;

- repeating the analysis excluding trials where the primary outcome data were gathered after more than 24 hours of chemotherapeutic treatment.


RESULTS

Description of studies

Results of the search

The search identified 441 records of which 135 were potentially eligible. We obtained hard copies of the full article of these articles for further consideration and excluded 112 (Figure 1). We identified no unpublished data.

Figure 1. Identification and selection of randomised controlled trials for review inclusion.



Included studies

Of the 23 included RCTs, the majority (19) were of cross-over design with four that were of parallel group design (Frytak 1979; Gralla 1984; Lane 1991; Pomeroy 1986).

The RCTs included people with a variety of cancers undergoing different chemotherapy regimens ranging from moderate to high anti-emetic potential, except for one of low emetic potential (Chang 1979a); five were unclassifiable as reporting of chemotherapy regimen was unclear (Kleinman 1983; Lane 1991; Levitt 1982; Sallan 1975a; Ungerleider 1982). Four trials were conducted on participants who were cannabis naive (Ahmedzai 1983; Frytak 1979; Johansson 1982; Lane 1991), one where 88% of participants were naive (Chang 1981), and one where 27% of participants were naive (Chang 1979a). One study excluded current users of cannabis (McCabe 1988), and in the other trials previous exposure to cannabinoids was unclear.

Nine RCTs compared cannabinoids given as monotherapy compared with placebo (Chang 1979a; Chang 1981; Frytak 1979; Jones 1982; Kluin-Neleman 1979; Levitt 1982; McCabe 1988; Sallan 1975a; Wada 1982), with another anti-emetic agent (prochlorperazine) in 11 RCTs (Ahmedzai 1983; Einhorn 1981; Frytak 1979; Herman 1979; Johansson 1982; Lane 1991; McCabe 1988; Niiranen 1985; Orr 1981; Steele 1980; Ungerleider 1982), metoclopramide in two RCTs (Crawford 1986; Gralla 1984), domperidone in one RCT (Pomeroy 1986), and chlorpromazine in one RCT (George 1983). Cannabinoids were also given as co-therapy with another anti-emetic agent compared with an anti-emetic agent alone in two RCTs (Kleinman 1983; Lane 1991). Two different cannabis-based medications were tested: nabilone in 12 RCTs (Ahmedzai 1983; Crawford 1986; Einhorn 1981; George 1983; Herman 1979; Johansson 1982; Jones 1982; Levitt 1982; Niiranen 1985; Pomeroy 1986; Steele 1980; Wada 1982), and dronabinol in 11 RCTs (Chang 1979a; Chang 1981; Frytak 1979;

Gralla 1984; Kleinman 1983; Kluin-Neleman 1979; Lane 1991; McCabe 1988; Orr 1981; Sallan 1975a; Ungerleider 1982).

Dosing schedules varied across trials. Nabilone when given as monotherapy was administered most commonly as a fixed dose of 2 mg twice daily with lower doses administered when given as co-therapy. Dronabinol was mainly given at doses according to body surface area and ranged from 10 mg/m² twice daily to 15 mg/m² six times daily. Both were given as an oral formulations. In two trials, oral dronabinol was replaced with cannabis-based cigarettes if the participants vomited (Chang 1979a; Chang 1981).

The majority of the nausea or vomiting (or both) outcomes were reported for those that occurred within a 24-hour period. However, for some trials, it was unclear when outcomes were assessed and they may have been reported for a longer time-period (Herman 1979; Johansson 1982; Jones 1982; Kluin-Neleman 1979; Lane 1991; Levitt 1982). Trials were conducted between 1975 and 1991.

Excluded studies

We excluded 112 studies for reasons described in the Characteristics of excluded studies table. The main reasons were due to not being a primary study (i.e. a review, editorial or letter) (64) or were a non-randomised single-arm study (eight). RCTs were excluded due to not being an eligible treatment group (six); comparison (six) or a relevant outcome (one); recruited children (three); only presenting preliminary (three) or subsidiary results (one); having no extractable data (eight) or a duplicate of an existing study (10). Two were unobtainable.

Risk of bias in included studies

The trials were of variable quality ranging from low to moderate (Figure 2; Figure 3).

Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials.




Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)
Ahmedzai 1983	?	?	-	+	?	+	+
Chang 1979a	+	?	-	+	+	+	+
Chang 1981	+	?	-	+	?	+	+
Crawford 1986	?	?	-	+	-	+	+
Einhorn 1981	?	+	+	+	?	+	+
Frytak 1979	+	+	+	+	+	+	+
George 1983	+	+	+	+	+	+	+
Gralla 1984	+	+	+	+	?	+	+
Herman 1979	?	+	?	+	?	+	+
Johansson 1982	?	?	-	+	?	+	+
...

Figure 3. (Continued)

Johansson 1982	?	?	-	+	?	+	+
Jones 1982	?	?	-	+	?	+	+
Kleinman 1983	?	?	+	+	?	+	+
Kluin-Neleman 1979	?	?	?	+	?	+	+
Lane 1991	?	?	+	+	+	+	+
Levitt 1982	?	?	-	+	?	+	+
McCabe 1988	?	?	+	+	?	-	-
Niiranen 1985	?	?	-	+	?	+	+
Orr 1981	?	?	-	+	?	+	+
Pomeroy 1986	?	?	+	+	?	+	+
Sallan 1975a	?	?	-	+	?	+	+
Steele 1980	?	?	-	+	?	+	+
Ungerleider 1982	+	?	+	+	+	+	+
Wada 1982	?	?	?	+	?	+	+

Allocation

Six trials adequately reported how the randomisation sequence was generated (Chang 1979a; Chang 1981; Frytak 1979; George 1983; Gralla 1984; Ungerleider 1982); the remaining 17 trials were unclear. Concealment of allocation was adequate in five trials (Einhorn 1981; Frytak 1979; George 1983; Gralla 1984; Herman 1979), and unclear in the remaining 18 trials.

Blinding

The majority of the trials were described as double-blind, which was implemented by using identical tablets. Eight were reported as double-blind, but it was unclear how this was achieved (Crawford 1986; Johansson 1982; Jones 1982; Lane 1991; Levitt 1982; Steele 1980; Ungerleider 1982; Wada 1982), and one study made no attempt at blinding (McCabe 1988).

Incomplete outcome data

Most trials were prone to attrition bias with only 9/23 trials judged as low risk of bias.

Selective reporting

All of the trials reported on the incidence of nausea or vomiting (or both); however, not all contributed to the meta-analyses. We were unable to include data for trials if they only reported results for nausea and vomiting as mean frequency of episodes, rather than the proportion of participants with and without nausea or vomiting (or both). While a reduction in severity of nausea or a reduction in vomiting episodes (or both) may be considered a worthwhile outcome for people with chemotherapy-induced nausea and vomiting, in these included trials, nausea severity was not measured with a validated instrument and episodes of vomiting were not analysed using standard methods for such (count) data. Therefore, we have not reported these data.

Other potential sources of bias

A large proportion of the trials were of cross-over design. We assumed that the washout period was sufficient and there were no carry-over effects of treatment due to the gap between chemotherapy treatment cycles, which would typically be around three weeks. The main potential source of bias was due to lack of information reported on whether a paired analysis was performed or not, and it was unclear if the groups were balanced at baseline.

Effects of interventions

See: [Summary of findings for the main comparison Cannabinoids compared with placebo for chemotherapy-induced nausea and vomiting](#); [Summary of findings 2 Cannabinoids compared with other anti-emetic agent for chemotherapy-induced nausea and vomiting](#); [Summary of findings 3 Cannabinoid plus other anti-emetic agent compared with other anti-emetic monotherapy for chemotherapy-induced nausea and vomiting](#)

Cannabinoids versus placebo

Nine trials with 819 participants compared cannabinoids with placebo (Chang 1979a; Chang 1981; Frytak 1979; Jones 1982; Kluin-Neleman 1979; Levitt 1982; Orr 1981; Sallan 1975a; Wada 1982), although not all trials contributed data for each outcome.

Primary outcome - anti-emetic efficacy

Two trials involving 96 participants showed no evidence of a difference between groups in the proportion of participants reporting complete absence of nausea with cannabinoids compared with placebo (RR 2.0; 95% CI 0.19 to 21; [Analysis 1.1](#)).

Three trials involving 168 participants showed that people had more chance of reporting complete absence of vomiting when they received cannabinoids compared with when they received placebo (RR 5.7; 95% CI 2.6 to 13). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important ($I^2 = 0\%$, $\text{Tau}^2 = 0.0$, Chi^2 test for heterogeneity P value = 0.33; [Analysis 1.2](#)).

Three trials involving 288 participants showed that people had more chance of reporting complete absence of nausea and vomiting when they received cannabinoids compared with placebo (RR 2.9; 95% CI 1.8 to 4.7). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important ($I^2 = 0\%$, $\text{Tau}^2 = 0.0$, Chi^2 test for heterogeneity P value = 0.50; [Analysis 1.3](#)).

Subgroup analyses, comparing results in trials with cannabis-naïve people to trials where participants either had previous experience with cannabis or where previous use was unclear, showed no evidence of a difference between the two subgroups (P value = 0.4) with respect to absence of nausea and vomiting.

Secondary outcome - participant preference

Two trials involving 256 participants showed that people had more chance of reporting a preference for cannabinoids compared with placebo (RR 4.8; 95% CI 1.7 to 13) with substantial heterogeneity ($I^2 = 71\%$, $\text{Tau}^2 = 0.43$, Chi^2 test for heterogeneity P value = 0.06; [Analysis 1.9](#)).

Secondary outcomes - tolerability and adverse events

One trial involving 33 participants showed no evidence of a difference between groups in the proportion of participants withdrawing for any reason (RR 0.31; 95% CI 0.01 to 7.21; [Analysis 1.10](#)).

Participants had more chance of withdrawing due to an adverse event when they received cannabinoids compared with placebo (2 trials; 226 participants; RR 6.9; 95% CI 2.0 to 24; [Analysis 1.11](#)), and less chance of withdrawing due to lack of efficacy (1 trial; 228 participants; RR 0.05; 95% CI 0.0 to 0.89; [Analysis 1.12](#)).

Participants had more chance of reporting 'feeling high' (3 trials; 137 participants; RR 31; 95% CI 6.4 to 152). The percentage of the variability in effect estimates that is due to heterogeneity rather than chance was not important ($I^2 = 0\%$, $\text{Tau}^2 = 0.0$, Chi^2 test for heterogeneity P value = 0.95; [Analysis 1.6](#)).

There was no evidence of a difference between groups in the proportion of participants reporting depression (1 trial; 16 participants; RR 3.8; 95% CI 0.18 to 80; [Analysis 1.4](#)), dysphoria (2 trials; 96 participants; RR 9.0; 95% CI 0.50 to 161; [Analysis 1.5](#)), paranoia (1 trial; 64 participants; RR 3.0; 95% CI 0.13 to 71; [Analysis 1.7](#)), or sedation (2 trials; 139 participants; RR 4.5; 95% CI 0.35 to 58; [Analysis 1.8](#)) with substantial heterogeneity ($I^2 = 72\%$, $\text{Tau}^2 = 2.65$, Chi^2 test for heterogeneity P value = 0.06).

The CIs for the estimates shown above are wide reflecting the uncertainty of these estimates.

Cannabinoids versus prochlorperazine

Nine trials with 1221 participants compared cannabinoids with prochlorperazine (Ahmedzai 1983; Frytak 1979; Herman 1979; Johansson 1982; Lane 1991; McCabe 1988; Niiranen 1985; Steele 1980; Ungerleider 1982), although not all trials contributed data for each outcome.

Primary outcome - anti-emetic efficacy

Five trials involving 258 participants showed no evidence of a difference between groups in the proportion of participants reporting no nausea (RR 1.5; 95% CI 0.67 to 3.2) with substantial heterogeneity ($I^2 = 58%$, $\text{Tau}^2 = 0.33$, Chi^2 test for heterogeneity P value = 0.05; Analysis 2.1).

Four trials involving 209 participants showed no evidence of a difference between groups in the proportion of participants reporting no vomiting (RR 1.1; 95% CI 0.86 to 1.4). The percentage of the variability in effect estimates that was due to heterogeneity rather than chance was not important ($I^2 = 0%$, $\text{Tau}^2 = 0.0$, Chi^2 test for heterogeneity P value = 0.53; Analysis 2.3).

Four trials involving 414 participants showed no evidence of a difference between groups in the proportion of participants reporting absence of nausea and vomiting (RR 2.0; 95% CI 0.74 to 5.4) with substantial heterogeneity ($I^2 = 60%$, $\text{Tau}^2 = 0.51$, Chi^2 test for heterogeneity P value = 0.06; Analysis 2.5). Sensitivity analysis, where the two parallel group trials were pooled after removal of the five cross-over trials, had an RR of 1.1 (95% CI 0.70 to 1.7) with no heterogeneity ($I^2 = 0%$, $\text{Tau}^2 = 0.0$, Chi^2 test for heterogeneity P value = 0.56).

Subgroup analyses - comparing results in trials with cannabis-naïve people to trials where participants either had previous experience with cannabis or where previous use was unclear, showed no evidence of a difference between the two subgroups with respect to absence of nausea (P value = 0.11), but a difference between the subgroups for absence of nausea and vomiting with a smaller effect in people with no previous cannabis use (P value = 0.007). We were unable to conduct a subgroup analysis for absence of vomiting as all trials were of people who were cannabis naïve (Analysis 2.6).

In addition, there was no evidence of a difference between subgroups comprised of different cannabinoid medications for absence of nausea (P value = 0.54), absence of vomiting (P value = 0.60) or absence of nausea and vomiting (P value = 0.10). The subgroup analyses did not explain the source of heterogeneity. There were insufficient data to perform other subgroup analyses listed in methods of analysis.

Secondary outcome - participant preference

Seven trials involving 695 participants showed participants had more chance of reporting a preference for cannabinoids compared with prochlorperazine (RR 3.2; 95% CI 2.2 to 4.7) with substantial heterogeneity ($I^2 = 53%$, $\text{Tau}^2 = 0.13$, Chi^2 test for heterogeneity P value = 0.05; Analysis 2.17).

Secondary outcomes - tolerability and adverse events

Based on one trial with 42 participants, participants had more chance of withdrawing for any reason (RR 3.5; 95% CI 1.4 to 8.9; Analysis 2.18), and due to lack of anti-emetic efficacy (RR 3.5; 95% CI 1.4 to 8.9; Analysis 2.20) when they received cannabinoids compared with prochlorperazine.

Five trials with 664 participants showed participants had more chance of withdrawing due to an adverse event when they received cannabinoids compared with prochlorperazine (RR 3.9; 95% CI 1.3 to 12) with unimportant heterogeneity ($I^2 = 17%$, $\text{Tau}^2 = 0.31$, Chi^2 test for heterogeneity P value = 0.31; Analysis 2.19).

Participants had more chance of reporting the following adverse events when they received cannabinoids compared with prochlorperazine: dizziness (7 trials; 675 participants; RR 2.4; 95% CI 1.8 to 3.1; unimportant heterogeneity: $I^2 = 12%$, $\text{Tau}^2 = 0.02$, Chi^2 test for heterogeneity P value = 0.34; Analysis 2.8), dysphoria (3 trials; 192 participants; RR 7.2; 95% CI 1.3 to 39; unimportant heterogeneity: $I^2 = 0%$, $\text{Tau}^2 = 0.0$, Chi^2 test for heterogeneity P value = 0.75; Analysis 2.9), euphoria (2 trials; 280 participants; RR 18; 95% CI 2.4 to 133; unimportant heterogeneity: $I^2 = 0%$, $\text{Tau}^2 = 0.00$, Chi^2 test for heterogeneity P value = 0.47; Analysis 2.10), 'feeling high' (4 trials; 389 participants; RR 6.2; 95% CI 3.5 to 11; unimportant heterogeneity: $I^2 = 0%$, $\text{Tau}^2 = 0.0$, Chi^2 test for heterogeneity P value = 0.75; Analysis 2.11), and sedation (8 trials; 947 participants; RR 1.4; 95% CI 1.2 to 1.8; moderate heterogeneity: $I^2 = 31%$, $\text{Tau}^2 = 0.02$, Chi^2 test for heterogeneity P value = 0.18; Analysis 2.15).

There was no evidence of a difference between groups in the proportion of participants reporting depression (3 trials; 317 participants; RR 0.81; 95% CI 0.51 to 1.3; unimportant heterogeneity: $I^2 = 0%$, $\text{Tau}^2 = 0.0$, Chi^2 test for heterogeneity P value = 0.47; Analysis 2.16), hallucinations (2 trials; 144 participants; RR 5.4; 95% CI 0.66 to 44; unimportant heterogeneity: $I^2 = 0%$, $\text{Tau}^2 = 0.0$, Chi^2 test for heterogeneity P value = 0.80; Analysis 2.12), postural hypotension (3 trials; 305 participants; RR 1.2; 95% CI 0.52 to 2.9; moderate heterogeneity: $I^2 = 41%$, $\text{Tau}^2 = 0.29$, Chi^2 test for heterogeneity P value = 0.18; Analysis 2.13), or paranoia (1 trial; 42 participants; RR 3.0; 95% CI 0.13 to 70; Analysis 2.14).

Cannabinoid versus metoclopramide

Two trials with 57 participants compared cannabinoid with metoclopramide (Crawford 1986; Gralla 1984), although both trials did not contribute data for each outcome.

Primary outcome - anti-emetic efficacy

Neither trial reported data for the proportion of participants with absence of nausea or vomiting (or both) (Crawford 1986; Gralla 1984).

Secondary outcome - participant preference

One trial involving 64 participants showed no evidence of a difference between groups in the proportion of participants reporting a preference for cannabinoids (RR 1.2; 95% CI 0.61 to 2.4; Analysis 2.17).

Secondary outcomes - tolerability and adverse events

Neither trial reported withdrawals.

Participants had more chance of reporting dizziness (1 trial, 30 participants; RR 12; 95% CI 1.8 to 81; [Analysis 2.8](#)), and postural hypotension (1 trial, 30 participants; RR 17; 95% CI 1.1 to 270; [Analysis 2.13](#)) when they received cannabinoids compared with metoclopramide. The CIs for these estimates were very wide reflecting the uncertainty of these estimates.

There was no evidence of a difference between groups in the proportion of participants reporting 'feeling high' (1 trial, 30 participants; RR 3.0; 95% CI 0.35 to 26; [Analysis 2.11](#)), or sedation (1 trial; 30 participants; RR 0.93; 95% CI 0.73 to 1.2; [Analysis 2.15](#)). The CIs for these estimates were very wide reflecting the uncertainty of these estimates. There were no dystonic reactions in either treatment group.

Cannabinoids versus domperidone

One trial with 38 participants compared cannabinoids versus domperidone ([Pomeroy 1986](#)).

Primary outcome - anti-emetic efficacy

The trial did not report data for the proportion of participants with absence of nausea or vomiting (or both).

Secondary outcome - participant preference

The trial did not report data for participant preference.

Secondary outcomes - tolerability and adverse events

There was no evidence of a difference between groups in the proportion of participants withdrawing due to lack of efficacy (RR 0.14; 95% CI 0.01 to 2.7; [Analysis 2.20](#)) or withdrawal due to an adverse event (RR 0.14; 95% CI 0.01 to 2.7; [Analysis 1.11](#)), with both estimates based on very low event rates.

Participants had more chance of reporting dizziness when they received cannabinoids compared with domperidone (RR 2.8; 95% CI 1.1 to 7.1; [Analysis 2.8](#)).

There was no evidence of a difference between groups in the proportion of participants reporting euphoria (RR 5.0; 95% CI 0.26 to 98; [Analysis 2.10](#)), postural hypotension (RR 4.0; 95% CI 0.49 to 33; [Analysis 2.13](#)) or sedation (RR 1.2; 95% CI 0.66 to 2.3; [Analysis 2.15](#)).

Cannabinoids versus chlorpromazine

One trial with 20 participants compared cannabinoids with chlorpromazine ([George 1983](#)).

Primary outcome - anti-emetic efficacy

The trial did not report data for anti-emetic efficacy.

Secondary outcome - participant preference

There was no evidence of a difference between groups in participants' preferences for treatment with cannabinoids or chlorpromazine (RR 2.0; 95% CI 0.83 to 4.8; [Analysis 2.17](#)).

Secondary outcomes - tolerability and adverse events

The trial did not report data for withdrawals.

There was no evidence of a difference between groups in the proportion of participants reporting euphoria (RR 3.0; 95% CI 0.13 to 70; [Analysis 2.10](#)), postural hypotension (RR 7.0; 95% CI 0.95 to 52;

[Analysis 2.13](#)), or sedation (RR 1.7; 95% CI 0.85 to 3.4; [Analysis 2.15](#)), with few events giving rise to wide CIs around the point estimates.

Cannabinoid plus other anti-emetic agent versus other anti-emetic agent monotherapy

Two trials with 105 participants compared cannabinoid plus other anti-emetic agent with other anti-emetic agent monotherapy ([Kleinman 1983](#); [Lane 1991](#)), although neither trial contributed data for all outcomes. The majority of the analyses were based on one small trial with few events ([Lane 1991](#)).

Primary outcome - anti-emetic efficacy

There was no evidence of a difference between groups in the proportion of participants reporting no nausea (RR 11; 95% CI 0.61 to 182; [Analysis 3.1](#)).

There was no evidence of a difference between groups in the proportion of participants reporting no vomiting (RR 1.5; 95% CI 0.69 to 3.1; [Analysis 3.2](#)).

There was no evidence of a difference between groups in the proportion of participants reporting no nausea or vomiting (RR 1.6; 95% CI 0.68 to 3.6; [Analysis 3.3](#)).

Secondary outcome - participant preference

The trials did not report data for participant preference.

Secondary outcomes - tolerability and adverse events

There was no evidence of a difference between groups in the proportion of participants withdrawing due to any reason (RR 1.3; 95% CI 0.41 to 4.2; [Analysis 3.9](#)).

There was no evidence of a difference between groups in the proportion of participants withdrawing due to an adverse event (RR 7.0; 95% CI 0.88 to 55; [Analysis 3.10](#)).

There was no evidence of a difference between groups in the proportion of participants withdrawing due to lack of efficacy (RR 0.12; 95% CI 0.01 to 2.0; [Analysis 3.11](#)).

There was no evidence of a difference between groups in the proportion of participants reporting depression (no participants in either group; [Analysis 3.4](#)), dizziness (RR 2.1; 95% CI 0.21 to 21; [Analysis 3.5](#)), dysphoria (RR 7.3; 95% CI 0.40 to 134; [Analysis 3.6](#)), paranoia (RR 5.2; 95% CI 0.27 to 103; [Analysis 3.7](#)), or sedation (RR 1.8; 95% CI 0.48 to 6.4; [Analysis 3.8](#)).

DISCUSSION

Summary of main results

The included trials showed that cannabinoids were more effective than placebo and were similar to conventional anti-emetics for treating chemotherapy-induced nausea and vomiting. However, despite causing more adverse events than placebo, overall there was weak evidence that people receiving chemotherapy for cancer preferred cannabinoids to placebo with stronger evidence that people preferred them to other anti-emetics.

Cannabinoids were highly effective. When compared with placebo, participants who received cannabinoids were five times as likely to report complete absence of vomiting, and three times as likely to

report complete absence of nausea and vomiting. Although, some participants were six times more likely to withdraw from the study due to an adverse event with cannabinoids, other participants were more likely to withdraw due to lack of efficacy with placebo. Adverse events associated with cannabinoids were reported, however, the only one with evidence of a difference between cannabinoids and placebo was 'feeling high'. Overall, there was weak evidence that participants preferred cannabinoids to placebo.

When cannabinoids were compared with conventional anti-emetic drugs, there was no evidence of a difference for nausea, vomiting, or nausea and vomiting. The majority of the data for these analyses were from comparison with prochlorperazine. However, participants were three or four times more likely to withdraw due to an adverse event with cannabinoids than prochlorperazine. Dizziness, dysphoria, 'feeling high' and sedation were all more likely with cannabinoids. Dizziness in particular was more likely with cannabinoids compared with metoclopramide and domperidone. Overall, there was evidence that participants preferred cannabinoids to conventional anti-emetics; however, the majority of the trials were of prochlorperazine.

There may be an additional benefit of administering a cannabinoid with another anti-emetic agent. These benefits include reduced nausea, vomiting, and nausea and vomiting. Adverse events were similar to those for comparisons with anti-emetics given as monotherapy, but there were insufficient data to make firm conclusions.

Overall completeness and applicability of evidence

The trials included in this review were on adults with a wide variety of cancers undergoing a wide range of chemotherapy regimens. Many of the trials included participants who were refractory to conventional anti-emetic medications. The synthetic cannabis-based compounds were given orally and were either dronabinol or nabilone. The most informative RCTs were the ones that compared a cannabis-based medication with a conventional anti-emetic, rather than placebo. These trials showed that cannabis-based medications had similar anti-emetic effects compared with prochlorperazine and metoclopramide.

Nowadays, people receiving moderate to highly emetogenic chemotherapy regimens will be prescribed combination prophylactic anti-emetic regimens including a 5-HT₃ antagonist and steroid, and perhaps also include a neurokinin-1 (NK-1) inhibitor for very highly emetogenic regimens (NCCN 2015). In the event of a person experiencing breakthrough or refractory, acute chemotherapy-induced nausea and vomiting, an additional agent from a different pharmacological class of anti-emetics would be recommended, such as metoclopramide, prochlorperazine or lorazepam (NCCN 2015). Cannabis-based anti-emetics offer an alternative additional anti-emetic agent for breakthrough or refractory acute chemotherapy-induced nausea and vomiting. Since there is a lack of studies that compare the use of cannabinoids to 5-HT₃ antagonists and NK-1 inhibitors, this review found no evidence to support the use of cannabinoids in place of current prophylactic combination anti-emetic regimens.

Quality of the evidence

Overall, the trials were of variable quality (very low to moderate by Grading of Recommendations Assessment, Development and Eval-

uation (GRADE) approach). Strengths included the use of blinding by using double-dummy preparations by the majority of the trials. However, it is possible that the trials were at risk of observer bias, due to the characteristic adverse effect profile of cannabinoids. The risk of bias from selective reporting of the primary outcome was low. The majority of the trials were unclear with respect to methods used to generate randomisation sequence and whether randomisation was concealed, so may be at risk of selection bias. A major weakness lies in the fact that a large proportion of the trials were of cross-over design, and we were unable to adjust the data to take into account the paired data, which will result in narrower CIs around effect estimates. Another weakness was high risk of bias from attrition from the trials. This was largely due to participants being excluded from analyses in the cross-over trials if they did not complete all cross-over periods. The summary of findings are shown in [Summary of findings for the main comparison](#); [Summary of findings 2](#); and [Summary of findings 3](#). The quality of the evidence for most outcomes was generally of low quality. The main reasons were due to risk of bias, imprecise results due to few studies or few events (or both) and unexplained heterogeneity. The impact of the downgrading decisions means that further research is likely to influence the confidence in our estimates of effects and may change the estimates.

Potential biases in the review process

Some trials only reported episodes of nausea and vomiting, rather than the proportion of participants with no nausea and vomiting, therefore we did not include these results in meta-analyses. We also analysed dichotomous outcomes from the cross-over studies without adjusting the analyses, which potentially gives rise to more precise (narrower CIs) estimates of effect.

In order to avoid publication bias, we searched for ongoing trials in clinical trial registry databases; however, we identified no further trials.

Agreements and disagreements with other studies or reviews

Our findings are in broad agreement with previously published systematic reviews (Machado Rocha 2008; Tramer 2001). We have updated and extended these earlier reviews by pooling placebo-controlled trials separately from trials with active comparison groups, and where cannabis was given as co-therapy with another anti-emetic, and reporting on tolerability as well as efficacy outcomes.

AUTHORS' CONCLUSIONS

Implications for practice

The widespread use of cannabis-based medicines for management of nausea and vomiting with chemotherapy is unlikely due to the adverse effects they cause. However, cannabinoids are a useful adjunctive treatment to consider for people on moderately or highly emetic chemotherapy that are refractory to other anti-emetic treatments, when all other options of therapy have been tried. Consideration needs to be made of the adverse effect profile of the cannabinoids, and how the adverse effects may be exacerbated with other concurrent anti-emetic treatments, as well as the age of the person. This systematic review will be valuable evidence for clinicians and future development of international guidelines to summarise the evidence available.

Implications for research

Adequate study design is important for anti-emetic studies, ideally using a double-blind trial design that is stratified for known prognostic factors, such as gender, age, alcohol intake, previous experience of chemotherapy, emetic potential of chemotherapy and a person's susceptibility to motion sickness (De Mulder 1992; Olver 1992a; Olver 1992b; Pater 1984). It is preferable for people to be chemotherapy naïve and receiving the same chemotherapy regimens, or, if that is not possible, to receive those of the same emetogenicity as classified by international guidelines. Uniform anti-emetic regimens should be used, when comparing an adjunctive anti-emetic being added to the regimen in one arm (Rhodes 1984). Studies that compare the use of newer anti-emetics that have efficacy for treating refractory nausea and vomiting (olanzapine and palonosetron) with cannabinoids would also be informative. It is difficult to compare anti-emetic studies (Martin 1992), due to the variation in anti-emetic doses, routes of administration, time periods of assessment of nausea and vomiting, assessment of episodes of nausea and vomiting, and any additional anti-emetics that may have been administered. It also needs to be clear whether acute or delayed (or both) nausea and vomiting is being assessed, and there is also a variation in the definitions of complete response across studies, which impacts on comparing studies (Pater 1984). In the original anti-emetic trials, assessment of nausea and vomiting has been inconsistent where no reliable and valid measures have been

used, which also impacts on their analysis and interpretation (Pater 1984; Rhodes 1984).

While cross-over trials are attractive to evaluate this type of therapy, they are susceptible to loss of participants if not all cross-over to the second and subsequent phases of the trial. Following recommendations of the CONSORT (Consolidated Standards of Reporting Trials) statement for cross-over studies would improve interpretation of such studies.

ACKNOWLEDGEMENTS

We thank Jo Morrison for clinical and editorial advice on the protocol, Jane Hayes for designing the search strategy and running the searches in all databases for us, Sarah Howcutt for translation of one article from French (George 1983), and Dax Steins for translation of one article from Dutch (Kluin-Nelemans 1981a). Finally, we thank Clare Jess and Gail Quinn for their contribution to the editorial process.

This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. The views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS) or the Department of Health.

REFERENCES

References to studies included in this review

Ahmedzai 1983 {published data only}

Ahmedzai S, Carlyle DL, Calder IT, Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. *British Journal of Cancer* 1983;**48**(5):657-63.

Chang 1979a {published data only}

Chang AE, Shiling DJ, Stillman RC. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. *Annals of Internal Medicine* 1979;**91**(6):819-24.

Chang 1981 {published data only}

Chang AE, Shiling DJ, Stillman RC. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. *Cancer* 1981;**47**(7):1746-51.

Crawford 1986 {published data only}

Crawford SM, Buckman R. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatin: a double blind study. *Medical Oncology and Tumor Pharmacotherapy* 1986;**3**(1):39-42.

Einhorn 1981 {published data only}

Einhorn LH, Nagy C, Furnas B, Williams SD. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. *Journal of Clinical Pharmacology* 1981;**21**(8-9 Suppl):64S-9S.

Frytak 1979 {published data only}

Frytak S, Moertel CG, O'Fallon JR. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. *Annals of Internal Medicine* 1979;**91**(6):825-30.

George 1983 {published data only}

George M, Pejovic MH, Thuair M, Kramar A, Wolff JP. Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin [French]. *Biomedicine & Pharmacotherapy* 1983;**37**(1):24-7.

Gralla 1984 {published data only}

Gralla RJ, Tyson LB, Bordin LA. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. *Cancer Treatment Reports* 1984;**68**(1):163-72.

Herman 1979 {published data only}

Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. *New England Journal of Medicine* 1979; Vol. 300:1295-7.

Johansson 1982 {published data only}

Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. *Cancer Treatment Reviews* 1982;**9**(Suppl B):25-33.

Jones 1982 {published data only}

Jones SE, Durant JR, Greco FA, Robertone A. A multi-institutional phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. *Cancer Treatment Reviews* 1982;**9**(Suppl B):45-8.

Kleinman 1983 {published data only}

Kleinman S, Weitzman SA, Cassem N, Andrews E. Double blind trial of delta-9-tetrahydrocannabinol (THC) versus placebo as an adjunct to prochlorperazine for chemotherapy-induced vomiting. *Current Therapeutic Research - Clinical and Experimental* 1983;**33**(61):1014-7.

Kluin-Neleman 1979 {published data only}

Kluin-Neleman JC, Neleman FA, Meuwissen OJ, Maes RA. Delta 9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo. *Veterinary & Human Toxicology* 1979;**21**(5):338-40.

Lane 1991 {published data only}

Lane M, Vogel CL, Ferguson J, Krasnow S, Sainers JL, Hamm J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. *Journal of Pain and Symptom Management* 1991;**6**(6):352-9.

Levitt 1982 {published data only}

Levitt M. Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. *Cancer Treatment Reviews*. 1982;**9**(Suppl B):49-53.

McCabe 1988 {published data only}

McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D, Schein PS. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. *Investigational New Drugs* 1988;**6**(3):243-6.

Niiranen 1985 {published data only}

Niiranen A, Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. *American Journal of Clinical Oncology: Cancer Clinical Trials* 1985;**8**(4):336-40.

Orr 1981 {published data only}

Orr LE, McKernan JF. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. *Journal of Clinical Pharmacology* 1981;**21**(8-9 Suppl):76S-80S.

Pomeroy 1986 {published data only}

Pomeroy M, Fennelly JJ, Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. *Cancer Chemotherapy and Pharmacology* 1986;**17**(3):285-8.

Sallan 1975a {published data only}

Sallan SE, Zinberg NE, Frei E. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer

chemotherapy. *New England Journal of Medicine* 1975; Vol. 293:795-7.

Steele 1980 {published data only}

Steele N, Gralla RJ, Braun Jr DW, Young CW. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. *Cancer Treatment Reports* 1980;**64**(2-3):219-24.

Ungerleider 1982 {published data only}

Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. *Cancer* 1982;**50**(4):636-45.

Wada 1982 {published data only}

Wada JK, Bogdon DL, Gunnell JC. Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. *Cancer Treatment Reviews* 1982;**9**(Suppl B):39-44.

References to studies excluded from this review

Aapro 1981 {published data only}

Aapro MS. Prevention of chemotherapy-induced nausea and vomiting in patients with cancer. *Arizona Medicine* 1981;**38**(11):843-5.

Allan 1987 {published data only}

Allan SG. Mechanisms and management of chemotherapy-induced nausea and vomiting. *Blood Reviews* 1987;**1**(1):50-7.

Anderson 1981 {published data only}

Anderson PO, McGuire GG. Delta-9-tetrahydrocannabinol as an antiemetic. *American Journal of Hospital Pharmacy* 1981;**38**(5):639-46.

Artim 1983 {published data only}

Artim R, Dibella N. [Tetrahydrocannabinol plus prochlorperazine for refractory nausea and vomiting]. Proceedings of the 19th annual meeting of the American Society of Clinical Oncology. 1983; Vol. 2:85.

Bateman 1982 {published data only}

Bateman DN, Rawlins MD. Therapeutic potential of cannabinoids. *British Medical Journal Clinical Research Ed* 1982;**284**(6324):1211-2.

Ben 2006 {published data only}

Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. *Journal of Ethnopharmacology* 2006;**105**(1-2):1-25.

Biedrzycki 2007 {published data only}

Biedrzycki BA. Evolving paradigms in chemotherapy-induced nausea and vomiting and symptom management for the breast cancer patient. *ONS Connect* 2007;**22**(8 suppl):9-10.

Broder 1982 {published data only}

Broder LE, Lean NL, Hilsenbeck SG. A randomized blinded clinical trial comparing delta-9-tetrahydrocannabinol (THC) and

hydroxyzine (HZ) as antiemetics (AE) for cancer chemotherapy (CT). *Proceedings of the American Association for Cancer Research* 1982;**23**:514.

Carey 1983 {published data only}

Carey MP, Burish TG, Brenner DE. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. *Annals of Internal Medicine* 1983;**99**(1):106-14.

Chan 1987 {published data only}

Chan HSL, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. *Pediatrics* 1987;**79**(6):946-52.

Chang 1979b {published data only}

Chang AE, Shiling DJ, Stillman RC. A prospective randomized trial of delta-9-tetrahydrocannabinol (THC) as an antiemetic in patients receiving high dose methotrexate (MTX). *American Society of Clinical Oncology* 1979:No-C-357.

Citron 1985 {published data only}

Citron ML, Herman TS, Vreeland F. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. *Cancer Treatment Reports* 1985;**69**(1):109-12.

Cocchetto 1981 {published data only}

Cocchetto DM, Cook LF, Cato AE. A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol. *Drug Intelligence and Clinical Pharmacy* 1981;**15**(11):867-75.

Colls 1980a {published data only}

Colls BM. Cannabis and cancer chemotherapy. *Lancet* 1980; Vol. 1:1187-8.

Colls 1980b {published data only}

Colls BM, Ferry DG, Gray AJ. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. *New Zealand Medical Journal* 1980;**91**(662):449-51.

Cone 1982 {published data only}

Cone LA, Greene DS, Helm NA. Use of nabilone in the treatment of chemotherapy-induced vomiting in an outpatient setting. *Cancer Treatment Reviews* 1982;**9**(Suppl B):63-70.

Costa 2007 {published data only}

Costa B. On the pharmacological properties of 9-tetrahydrocannabinol (THC). *Chemistry and Biodiversity* 2007;**4**(8):1664-77.

Cotter 2009 {published data only}

Cotter J. Efficacy of crude marijuana and synthetic delta-9-tetrahydrocannabinol as treatment for chemotherapy-induced nausea and vomiting: a systematic literature review. *Oncology Nursing Forum* 2009; Vol. 36, issue 3:345-52.

Cronin 1981 {published data only}

Cronin CM, Sallan SE, Gelber R, Lucas VS, Laszlo J. Antiemetic effect of intramuscular levonantradol in patients receiving

anticancer chemotherapy. *Journal of Clinical Pharmacology* 1981;**21**(8-9 Suppl):43S-50S.

Croxford 2003 {published data only}

Croxford JL. Therapeutic potential of cannabinoids in CNS disease. *CNS Drugs* 2003;**17**:179-202.

Cunningham 1985 {published data only}

Cunningham D, Forrest GJ, Soukop M. Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs. *British Medical Journal* 1985;**291**(6499):864-5.

Cunningham 1988 {published data only}

Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, et al. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. *European Journal of Cancer and Clinical Oncology* 1988;**24**(4):685-9.

Dalzell 1986 {published data only}

Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. *Archives of Disease in Childhood* 1986;**61**(5):502-5.

Darmani 2010 {published data only}

Darmani NA. Cannabinoid-induced hyperemesis: a conundrum-from clinical recognition to basic science mechanisms. *Pharmaceuticals* 2010;**3**(7):2163-77.

Davis 2007 {published data only}

Davis M, Maida V, Daeninck P, Pergolizzi J. The emerging role of cannabinoid neuromodulators in symptom management. *Supportive Care in Cancer* 2007;**15**(1):63-71.

Davis 2008 {published data only}

Davis MP. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. *Expert Opinion on Investigational Drugs* 2008;**17**(1):85-95.

Devine 1987 {published data only}

Devine ML, Dow GJ, Greenberg BR, Holstein DW, Icaza L, Jue PY, et al. Adverse reactions to delta-9-tetrahydrocannabinol given as an antiemetic in a multicenter study. *Clinical Pharmacy* 1987;**6**(4):319-22.

Dodds 1985 {published data only}

Dodds LJ. The control of cancer chemotherapy-induced nausea and vomiting. *Journal of Clinical Hospital Pharmacy* 1985;**10**(2):143-66.

Dow 1984 {published data only}

Dow GJ, Meyers FH, Stanton W, Devine ML. Serious reactions to oral delta-9-tetrahydrocannabinol in cancer chemotherapy patients. *Clinical Pharmacy* 1984;**3**(1):14.

Duran 2010 {published data only}

Duran M, Perez E, Abanades S, Vidal X, Saura C, Majem M, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced

nausea and vomiting. *British Journal of Clinical Pharmacology* 2010;**70**(5):656-63.

Ekert 1979 {published data only}

Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. *Medical Journal of Australia* 1979;**2**(12):657-9.

Ettinger 2007 {published data only}

Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, et al. Antiemesis: clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network* 2007;**5**(1):12-33.

Feyer 2011 {published data only}

Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. *Annals of Oncology* 2011;**22**(1):30-8.

Fiore 1984 {published data only}

Fiore JJ, Gralla RJ. Pharmacologic treatment of chemotherapy-induced nausea and vomiting. *Cancer Investigation* 1984;**2**(5):351-61.

Fox 1979 {published data only}

Fox FJ, Baker JJ, Lokey JL. Nabilone as an antiemetic. *New England Journal of Medicine* 1979;**301**(13):728.

Galal 2009 {published data only}

Galal AM, Slade D, Gul W, El-Alfy AT, Ferreira D, Elshohly MA. Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. *Recent Patents on CNS Drug Discovery* 2009;**4**(2):112-36.

Gallego 1984 {published data only}

Gallego Fernandez C, Ferrandiz Gosalbez JR. Nausea and vomiting induced by cancer chemotherapy. Review of Cannabis and its antiemetic effects. *Farmacia Clinica* 1984;**1**(9):51-62.

Gerhartz 1983 {published data only}

Gerhartz HH, Binsack T, Hiller E. Levonantradol for the treatment of chemotherapy-induced nausea and vomiting. *Klinische Wochenschrift* 1983;**61**(14):719-21.

Gerra 2010 {published data only}

Gerra G, Zaimovic A, Gerra ML, Ciccocioppo R, Cippitelli A, Serpelloni G, et al. Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. *Recent Patents on CNS Drug Discovery* 2010;**5**(1):46-52.

Goodman 1997 {published data only}

Goodman M. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting. *Oncology Nursing Forum* 1997;**24**(7 Suppl):20-32.

Gorter 1999 {published data only}

Gorter RW. Cancer cachexia and cannabinoids. *Forschende Komplementarmedizin* 1999;**6**(Suppl 3):21-2.

Grunberg 1989 {published data only}

Grunberg SM. Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. *Blood Reviews* 1989;**3**(4):216-21.

Guzman 2003 {published data only}

Guzman M. Cannabinoids: potential anticancer agents. *Cancer* 2003;**3**(10):745-55.

Heim 1984 {published data only}

Heim ME, Queisser W, Altenburg HP. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy. *Cancer Chemotherapy and Pharmacology* 1984;**13**(2):123-5.

Herrstedt 1998 {published data only}

Herrstedt J, Aapro MS, Smyth JF, Del Favero A. Corticosteroids, dopamine antagonists and other drugs. *Supportive Care in Cancer* 1998;**6**(3):204-14.

Herrstedt 2008 {published data only}

Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. *Nature Clinical Practice Oncology* 2008;**5**(1):32-43.

Higi 1982 {published data only}

Higi M, Niederle N, Bremer K, Schmitt G, Schmidt CG, Seeber S. Levonantradol in the treatment of nausea and vomiting caused by cytostatic drugs (author's translation) clinical studies [German]. *Deutsche Medizinische Wochenschrift* 1982;**107**(3):1232-4.

Hiller 1984 {published data only}

Hiller E, Gerhartz H. New aspects in the antiemetic therapy of cytostatic drug-induced vomiting [German]. *Klinische Wochenschrift* 1984;**62**(10):441-5.

Hutcheon 1983 {published data only}

Hutcheon AW, Palmer JBD, Soukop M. A randomised multicentre single blind comparison of cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. *European Journal of Cancer and Clinical Oncology* 1983;**19**(8):1087-90.

Jordan 2007 {published data only}

Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. *Critical Reviews in Oncology-Hematology* 2007;**61**(2):162-75.

Jordan 2011 {published data only}

Jordan K, Roila F, Molassiotis A, Maranzano E, Clark-Snow RA, Feyer P, et al. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. *Supportive Care in Cancer* 2011;**19**(Suppl 1):S37-42.

Kearsley 1985 {published data only}

Kearsley JH, Tattersall MH. Recent advances in the prevention or reduction of cytotoxic-induced emesis. *Medical Journal of Australia* 1985;**143**(8):341-6.

Kenny 1982 {published data only}

Kenny JB, Wilkinson PM. Levonantradol effectiveness in cancer patients resistant to conventional anti-emetics. *Clinical Oncology* 1982;**8**(4):335-9.

Kluin-Nelemans 1981a {published data only}

Kluin-Nelemans JC, Meuwissen Th OJA, Nelemans FA, Maes RAA. Tetrahydrocannabinol as antiemetic in patients treated with cytostatics: double blind crossover trial against placebo. *Nederlands Tijdschrift voor Geneeskunde* 1981;**125**(2):900-1.

Kluin-Nelemans 1981b {published data only}

Kluin-Nelemans JC, Meuwissen Th OJA, Nelemans FA, Maes RAA. 9-Tetrahydrocannabinol (THC) as an anti-emetic in patients treated with cancer chemotherapy. A double-blind cross-over trial against placebo. *Netherlands Journal of Medicine* 1981;**24**(2):90.

Krasnow 1991 {published data only}

Krasnow SH. New directions in managing chemotherapy-related emesis. *Oncology* 1991;**5**(9 Suppl):19-24.

Kreutz 2007 {published data only}

Kreutz S. The magic plant as an antiemetic. Cannabinoids for treatment of nausea and vomiting [German]. *Pharmazie in Unserer Zeit* 2007;**36**(5):389-92.

Lane 1989 {published data only}

Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JH, Hamm J, et al. Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Proceedings of the American Society of Clinical Oncology 1989; Vol. 8:326, Abstract 1269.

Lane 1990 {published data only}

Lane M, Smith FE, Sullivan RA, Plasse TF. Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. *American Journal of Clinical Oncology: Cancer Clinical Trials* 1990;**13**(6):480-4.

Laszlo 1982 {published data only}

Laszlo J. Treatment of nausea and vomiting caused by cancer chemotherapy. *Cancer Treatment Reviews* 1982;**9**(Suppl B):3-9.

Levitt 1981 {published data only}

Levitt M, Wilson A, Bowman D, Kemel S, Krepart G, Marks V, et al. Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications. *Journal of Clinical Pharmacology* 1981;**21**(8-9 Suppl):103S-9S.

Levitt 1984 {published data only}

Levitt M, Faiman C, Hawks R, Wilson A. Randomized double blind comparison of delta-9-tetrahydrocannabinol and marijuana as chemotherapy antiemetics [abstract]. Proceedings - Annual Meeting of American Society of Clinical Oncology 1984; Vol. 3:91, Abstract C-354.

Lohr 2008 {published data only}

Lohr L. Chemotherapy-induced nausea and vomiting. *Cancer Journal* 2008;**14**(2):85-93.

Long 1982 {published data only}

Long A, Mioduszewski JNR. A randomized double-blind cross-over comparison of the antiemetic activity of levonantradol and prochlorperazine. *Proceedings of the American Society of Clinical Oncology* 1982;**1**:C-220.

Machado 2008 {published data only}

Machado Rocha FC, Stefano SC, De Cassia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. *European Journal of Cancer Care* 2008;**17**(5):431-43.

Mechoulam 1978 {published data only}

Mechoulam R, Carlini EA. Toward drugs derived from cannabis. *Naturwissenschaften* 1978;**65**(4):174-9.

Mechoulam 1999 {published data only}

Mechoulam R. Recent advantages in cannabinoid research. *Forschende Komplementarmedizin* 1999;**6**(Suppl 3):16-20.

Mechoulam 2001 {published data only}

Mechoulam R, Hanus L. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. *Pain Research and Management* 2001;**6**(2):67-73.

Meiri 2007 {published data only}

Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. *Current Medical Research and Opinion* 2007;**23**(3):533-43.

Murakami 1986 {published data only}

Murakami M, Ota K. Recent advances in the management of chemotherapy-induced emesis [Japanese]. *Japanese Journal of Cancer Chemotherapy* 1986;**13**(3):401-11.

Musty 2001 {published data only}

Musty RE, Rossi R. Effects of smoked cannabis and oral DELTA9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: a review of state clinical trials. *Journal of Cannabis Therapeutics* 2001; Vol. 1, issue 1:29.

Nagy 1978 {published data only}

Nagy CM, Furnas BA, Einhorn LH, Bond WH. Nabilone (N) anti-emetic crossover study in cancer chemotherapy patients. *American Association for Cancer Research and American Society of Clinical Oncology* 1978;**19**:30.

Navari 2009a {published data only}

Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting. *Drugs* 2009;**69**(5):515-33.

Navari 2009b {published data only}

Navari RM. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. *Expert Opinion on Pharmacotherapy* 2009;**10**(4):629-44.

Niederle 1986 {published data only}

Niederle N, Schutte J, Schmidt CG. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. *Klinische Wochenschrift* 1986;**64**(8):362-5.

Niiranen 1987 {published data only}

Niiranen A, Mattson K. Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. *American Journal of Clinical Oncology* 1987;**10**(4):325-9.

Nyman 1982 {published data only}

Nyman JV, Fritz WL. A review of the antiemetic use of delta-9-tetrahydrocannabinol and prescribing requirements. *Arizona Medicine* 1982;**39**(1):38-43.

Orr 1980 {published data only}

Orr LE, McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. *Archives of Internal Medicine* 1980;**140**(11):1431-3.

Penta 1981 {published data only}

Penta JS, Poster DS, Bruno S, Macdonald JS. Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. *Journal of Clinical Pharmacology* 1981;**21**(8-9):11S-22S.

Perwitasari 2011 {published data only}

Perwitasari DA, Gelderblom H, Atthobari J, Mustofa M, Dwiprahasto I, Nortier JWR, et al. Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. *International Journal of Clinical Pharmacy* 2011;**33**(1):33-43.

Phillips 2010 {published data only}

Phillips RS, Gopaul S, Gibson F, Houghton E, Craig JV, Light K, et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. *Cochrane Database of Systematic Reviews* 2010, Issue 9. [DOI: [10.1002/14651858.CD007786.pub2](https://doi.org/10.1002/14651858.CD007786.pub2)]

Plasse 1991 {published data only}

Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. *Pharmacology, Biochemistry and Behavior* 1991;**40**(3):695-700.

Porta 2002 {published data only}

Porta I, Sales J, Schoenenberger I, Arnaiz JA. Cannabinoids, a myth or a scientific reality?. *Medicina Paliativa* 2002;**9**(3):129-33.

Poster 1981 {published data only}

Poster DS, Penta JS, Bruno S, Macdonald JS. Delta 9-tetrahydrocannabinol in clinical oncology. *JAMA* 1981;**245**(20):2047-51.

Reynolds 2002 {published data only}

Reynolds R. Comparative efficacy of dronabinol and megestrol acetate. *Journal of Clinical Oncology* 2002;**20**(12):2912-3; author reply 2913.

Sallan 1975b {published data only}

Sallan S, Zinberg N, Frei E. Oral delta 9 tetrahydrocannabinol (THC) in the prevention of vomiting (V) associated with cancer chemotherapy (CC). Annual Meeting, proceedings of the American Association for Cancer Research 1975; Vol. 16:575.

Sallan 1980 {published data only}

Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. *New England Journal of Medicine* 1980;**302**(3):135-8.

Schuette 1985 {published data only}

Schuette J, Niederle N, Kruschke W. Randomized crossover trial comparing the antiemetic efficacy of nabilone versus alizapride in patients (pts) with nonseminomatous testicular cancer (NSTC) receiving low-dose cisplatin therapy. *Proceedings of the American Association for Cancer Research* 1985;**26**:665.

Sheidler 1984 {published data only}

Sheidler VR, Ettinger DS, Diasio RB, Enterline JP, Brown MD. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. *Journal of Clinical Pharmacology* 1984;**24**(4):155-9.

Slatkin 2007 {published data only}

Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. *Journal of Supportive Oncology* 2007;**5**(Suppl 3):1-9.

Smith 2007 {published data only}

Smith PF. Will medicinal cannabinoids prove to be useful clinically?. *Current Drug Therapy* 2007;**2**(2):143-50.

Stambaugh 1982 {published data only}

Stambaugh JE, McAdams J, Vreeland F. A phase II randomized trial of the antiemetic activity of levonantradol (CP-50,556) in cancer patients receiving chemotherapy. *Proceedings of the American Society of Clinical Oncology* 1982;**1**:C-240.

Stambaugh 1984 {published data only}

Stambaugh Jr JE, McAdams J, Vreeland F. Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. *Journal of Clinical Pharmacology* 1984;**24**(11-12):480-5.

Steele 1979 {published data only}

Steele N, Braun D, O'Hehir M, Young C. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. *Cancer Treatment Reports* 1979; Vol. 64, issue 2-3:219-24.

Stewart 1990 {published data only}

Stewart DJ. Cancer therapy, vomiting, and antiemetics. *Canadian Journal of Physiology & Pharmacology* 1990;**68**(2):304-13.

Stuart 1982 {published data only}

Stuart JFB, Welsh Sangster G, Scullion M, Cash H, Kaye SB, Calman KC. The anti-emetic potential of oral levonantradol in patients receiving cancer chemotherapy. *British Journal of Cancer* 1982; Vol. 46:492.

Stuart-Harris 1983 {published data only}

Stuart-Harris RC, Mooney CA, Smith IE. Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy. *Clinical Oncology* 1983;**9**(2):143-6.

Sweet 1980 {published data only}

Sweet DL. Marijuana for drug-induced nausea and vomiting. *JAMA* 1980;**243**(12):1265.

Toth 2008 {published data only}

Toth J, Szanto J. Prophylaxis of chemotherapy-induced vomiting and nausea [Hungarian]. *Magyar Onkologia* 2008;**52**(4):391-4.

Tramer 2001 {published data only}

Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. *BMJ* 2001;**323**(7303):16-21.

Ungerleider 1985 {published data only}

Ungerleider JT, Sarna G, Fairbanks LA, Goodnight J, Andrysiak T, Jamison K. THC or compazine for the cancer chemotherapy patient - the UCLA study. Part II: patient drug preference. *American Journal of Clinical Oncology* 1985;**8**(2):142-7.

Venner 1986 {published data only}

Venner P, Bruera E, Drebit D, Shankowsky H. Intensive treatment scheduling of nabilone plus dexamethasone (DM) vs metoclopramide plus DM in cisplatin-induced emesis. *Proceedings of the American Society of Clinical Oncology* 1986;**5**:253.

Vincent 1983 {published data only}

Vincent BJ, McQuiston DJ, Einhorn LH. Review of cannabinoids and their antiemetic effectiveness. *Drugs* 1983;**25**(Suppl 1):52-62.

Voth 1997 {published data only}

Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. *Annals of Internal Medicine* 1997;**126**(10):791-8.

Wang 2008 {published data only}

Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. *Canadian Medical Association Journal* 2008;**178**(13):1669-78.

Ward 1985 {published data only}

Ward A, Holmes B, Nabilone. A preliminary review of its pharmacological properties and therapeutic use. *Drugs* 1985;**30**(2):127-44.

Ware 2008 {published data only}

Ware MA, Daeninck P, Maida V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. *Therapeutics and Clinical Risk Management* 2008;**4**(1):99-107.

Zuardi 2008 {published data only}

Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. *Revista Brasileira de Psiquiatria* 2008;**30**(3):271-80.

References to studies awaiting assessment
Citron 1983 {published data only}

Citron ML, Herman TS, Fossieck BE, Krasnow SH, Vreeland F, Harwood S, et al. Double-blind, randomised, crossover study of the antiemetic effect of levonantradol versus tetrahydrocannabinol. *Proceedings of the American Association of Cancer Research* 1983;**24**:165.

Earhart 1983 {published data only}

Earhart RH, Koeller JM. Levonantradol vs prochlorperazine as parenteral antiemetics in cancer patients receiving cisplatin chemotherapy. *Proceedings of the American Association for Cancer Research*. 1983;**24**:163.

Jhangiani 2005 {published data only}

Jhangiani H, Vredenburgh J, Barbato L, Yang H, Yang H M, Baranowski V, et al. Dronabinol or ondansetron alone and combined for delayed chemotherapy-induced nausea and vomiting (CINV). Abstracts for the 47th Annual Meeting of the American Society of Hematology; 2005 Dec 10-13; Atlanta, Georgia 2005; Vol. 106:477.

Neidhart 1981 {published data only}

Neidhart JA, Gagen MM, Wilson HE, Young DC. Comparative trial of the antiemetic effects of THC and haloperidol. *Journal of Clinical Pharmacology* 1981;**21**(8-9 Suppl):38S-42S.

Additional references
Barowski 1984

Barowski MT. Advances in anti-emetic therapy. *Cancer Treatment Reviews* 1984;**11**:237-56.

Basch 2011

Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. *Journal of Clinical Oncology* 2011;**29**(31):4189-96.

Beusterien 2014

Beusterien K, Grinspan J, Kuchuk I, Mazzarello S, Dent S, Gertler S, et al. Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. *Oncologist* 2014;**19**(2):127-34.

Bonnie 1974

Bonnie RJ, Whitebread CH. *The Marijuana Conviction: a History of Marijuana Prohibition in the United States*. Charlottesville, VA: University Press of Virginia: The Lindesmith Center, 1974.

Cohen 1988

Cohen, J. *Statistical power analysis for the behavioural sciences*. Statistical power analysis for the behavioural sciences. 2nd Edition. New Jersey: Lawrence Erlbaum, 1988.

Darmani 2001

Darmani NA. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB (1) receptor antagonist/inverse agonist SR 141716A. *Neuropsychopharmacology* 2001;**24**:198-203.

de Boer-Dennert 1997

de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. *British Journal of Cancer* 1997;**76**(8):1055-61.

De Mulder 1992

De Mulder PHM. Measurement of success: parameters of efficacy. *British Journal of Cancer* 1992;**66**(Suppl XIX):S68.

Deeks 2001

Deeks JJ, Altman DG, Bradburn MJ. *Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis*. Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ, 2001:285-312.

Devane 1992

Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 1992;**258**:1946-9.

Dubey 2005

Dubey S, Brown RL, Esmond SL, Bowers BJ, Healy JM, Schiller JH. Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer. *Journal of Supportive Oncology* 2005;**3**(2):149-54.

Gralla 1999

Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. *Journal of Clinical Oncology* 1999;**17**(9):2971-94.

Gralla 2013

Gralla RJ, Roila F, Tonato M, Herstedt J. MASCC antiemetic guidelines, 2013. www.mascc.org/antiemetic-guidelines (accessed 29 October 2015).

Grotenhermen 2002

Grotenhermen F. *Effects of cannabis and the cannabinoids*. In: Grotenhermen F, Russo E editor(s). *Pharmacology, Toxicology and Therapeutic Potential*. 1st Edition. New York: The Haworth Press, Inc., 2002:55-65.

Higgins 2003

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557-60.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Huang 2004

Huang JQ, Zheng GF, Chan GC, Karlberg J, Lam SK, Wong BC. Efficacy of current antiemetic treatments for preventing delayed chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials. *Clinical Research and Regulatory Affairs* 2004;**21**(3-4):191-212.

Ioannidis 2000

Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. *Journal of Clinical Oncology* 2000;**18**:3409-22.

Janelsins 2013

Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. *Expert Opinion on Pharmacotherapy* 2013;**14**(6):757-66.

Karniol 2001

Karniol IG. Cannabis sativa and derivatives. In: Seibel SD, Toscano JRA editor(s). Dependência de Drogas. 1st Edition. Rio de Janeiro: Atheneu, 2001:131-42.

Kuchuk 2013

Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. *Breast Cancer Research and Treatment* 2013;**142**(1):107.

Machado Rocha 2008

Machado Rocha FC, Stefano SC, De Cássia Haiek R, Rosa Oliveira LMQ, da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. *European Journal of Cancer Care* 2008;**17**(5):431-43.

Martin 1992

Martin M. Myths and realities of antiemetic treatment. *British Journal of Cancer* 1992;**66**(Suppl XIX):S46-51.

MASCC 1998

Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). *Annals of Oncology* 1998;**9**(8):811-9.

Mechoulam 1995

Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochemical Pharmacology* 1995;**50**:83-90.

NCCN 2014

National Comprehensive Cancer Network (NCCN). National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) Antiemesis Version 2, 2014. www.nccn.org/professionals/physician_gls/f_guidelines.asp, last retrieved 09.11.15.

NCCN 2015

National Comprehensive Cancer Network (NCCN). National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Antiemesis Version 2. http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf, last retrieved 09.11.15.

Olver 1992a

Olver IN. Methodology in anti-emetic trials. *Oncology* 1992;**49**:269-72.

Olver 1992b

Olver IN. Antiemetic study design: desirable objectives, stratifications and analyses. *British Journal of Cancer* 1992;**66**(Suppl XIX):S30-4.

Olver 2004

Olver I. Two decades of progress in treating chemotherapy induced emesis. *Cancer Forum* 2004;**28**:140-3.

Pater 1984

Pater JL, Willan AR. Methodologic issues in trials of antiemetics. *Journal of Clinical Oncology* 1984;**2**(5):484-7.

Rhodes 1984

Rhodes VA, Watson PM, Johnson MH. Development of reliable and valid measures of nausea and vomiting. *Cancer Nursing* 1984;**7**(1):33-41.

Rodríguez de Fonseca 2005

Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. *Alcohol and Alcoholism* 2005;**40**(1):2-14.

Roila 2010

Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. *Annals of Oncology* 2010;**21**(5):232-43.

Russo 2014

Russo S, Cinausero M, Gerratana L, Bozza C, Iacono D, Driol P, et al. Factors affecting patient's perception of anticancer treatments side-effects: an observational study. *Expert Opinion on Drug Safety* 2014;**13**(2):139-50.

Schwartzberg 2007

Schwartzberg LS. Chemotherapy-induced nausea and vomiting: clinician and patient perspective. *Journal of Support Oncology* 2007;**5**:5-12.

Sugiura 1995

Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochemical and Biophysical Research Communications* 1995;**215**:89-97.

Sun 2002

Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, et al. Patient preferences regarding side

effects of chemotherapy for ovarian cancer: do they change over time?. *Gynecologic Oncology* 2002;**87**(1):118-28.

Walsh 2003

Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. *Supportive Care in Cancer* 2003;**11**:137-43.

Wilcox 1982

Wilcox PM, Fetting JH, Nettesheim KM, Abeloff MD. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. *Cancer Treatment Reports* 1982;**66**:1601-4.

CHARACTERISTICS OF STUDIES
Characteristics of included studies [ordered by study ID]
Ahmedzai 1983

Methods	Randomised, double-blinded, 2-period cross-over study
Participants	34 people (19 (56%) men/15 (44%) women), median age 58 years. All cannabis naive Tumour types: small cell bronchial carcinoma Chemotherapy regimen: 2 x 21-day cycles. Cyclophosphamide 1 g/m ² , doxorubicin 40 mg/m ² and etoposide (VP-16) 100 mg/m ² day 1; etoposide 100 mg/m ² days 2 and 3; vincristine 2 mg with methotrexate 50 mg/m ² day 10 followed by folinic acid rescue. Cyclophosphamide and doxorubicin given IV bolus; VP-16 IV over 1-2 hours Chemotherapy emetogenicity: High
Interventions	Nabilone 2 mg orally twice daily x 3 days, n = 34 Prochlorperazine 10 mg orally 3 times daily x 3 days, n = 34
Outcomes	Episodes and frequency of nausea and vomiting day 1; withdrawal due to adverse effects; withdrawals due to death; participant preference due to adverse effects; incidence of feeling high, euphoria, postural dizziness, dysphoria
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	8/34 (24%) participants withdrew
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome

Ahmedzai 1983 (Continued)

Other bias	Unclear risk	Approximately 10 days' washout period. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Double dummy tablet"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind" and dummy tablet used

Chang 1979a

Methods	Randomised, double-blind, 3-period cross-over, placebo-controlled trial	
Participants	15 people (10/15 (67%) men/5/15 (33%) women) aged 15-49 years (median = 24 years). 4/15 (27%) participants were cannabis naive Tumour type: osteogenic sarcoma Chemotherapy regimens: methotrexate 250 mg/kg with leucovorin calcium rescue every 3 weeks for 18 months Chemotherapy emetogenicity: low	
Interventions	Dronabinol 10 mg/m ² orally every 3 hours for total 5 doses (Phase I), n = 15. If participant vomited during this period oral dose was replaced with THC cigarette for remaining doses Placebo, n = 15	
Outcomes	Episodes of nausea and vomiting on day of therapy; frequency and severity of nausea; episodes of sedation, euphoria, dizziness, depression, paranoia	
Notes		

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Order of THC-placebo administration was randomized into three paired trials"
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	58/77 (75%) participants received THC, 39/53 (74%) participants received placebo
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Low risk	Groups balanced at baseline

Chang 1979a (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical gelatin capsules with sesame oil". "Identical cigarettes, the odour and taste of a lit placebo cigarette were identical to those of cannabis cigarette"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind"

Chang 1981

Methods	Randomised, double-blind, 3-period cross-over trial
Participants	8 people (6/8 (75%) men/2/8 (25%) women) aged 17-58 years (median = 41 years), 7/8 (88%) participants were cannabis naive Tumour types: resected soft tissue sarcoma Chemotherapy regimen: adjuvant doxorubicin and cyclophosphamide every 4 weeks until a total cumulative doxorubicin dose of 500-550 mg/m ² Doxorubicin (70 mg/m ²) and cyclophosphamide (700 mg/m ²) were given at constant doses for all participants Chemotherapy emetogenicity: high
Interventions	Dronabinol 10 mg/m ² orally every 3 hours for total 5 doses, if vomited then participant given marijuana cigarettes 900 mg, containing THC 1.93% (approximately 17.4 mg), n = 8 Placebo, n = 8
Outcomes	Episodes of nausea and vomiting on day of therapy
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Order of THC-placebo administration was randomized into paired trials"
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	17/27 (63%) participants received THC, 16/27 (59%) participants received placebo
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Paired analysis was performed. Unclear if groups balanced at baseline
Blinding of participants and personnel (performance bias)	Low risk	"Identical gelatin capsules with sesame oil. Identical cigarettes, the odour and taste of a lit placebo cigarette were identical to those of cannabis cigarette"

Chang 1981 (Continued)

All outcomes

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind". "Neither patients nor nursing staff was [sic] informed which drug was administered"
-----------------------------------------------------------------	----------	-------------------------------------------------------------------------------------------------------------------------------------------

Crawford 1986

Methods	Randomised, 2-period cross-over study
Participants	32 people Tumour type: adenocarcinoma of the ovary or germ cell tumours. Chemotherapy regimen: cisplatin 100 mg/m ² , cyclophosphamide and doxorubicin (for people with adenocarcinoma of ovary), cisplatin 120 mg/m ² , methotrexate and vincristine (for people with germ cell tumours). No information on doses reported Chemotherapy emetogenicity: high
Interventions	Nabilone 1 mg orally every 8 hours, n = 32 Metoclopramide 1 mg/kg IV every 3 hours, n = 32
Outcomes	Episodes of vomiting during 24 hours, nausea, dizziness, euphoria and drowsiness

Notes

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	7/32 (22%) participants received the 4 planned treatment and only 37/64 (58%) participants received 1 or 2 treatment episodes of nabilone and 39/64 (61%) participants received 1 or 2 treatment episodes of metochlopramide
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	High risk	Assumed washout period sufficient. Paired analysis was not performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as "double-blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind"

Einhorn 1981

Methods	Randomised, prospective, double-blind, 2-period cross-over study
Participants	<p>100 people aged 15-74 years, mean = 28 years</p> <p>Tumour type; sarcoma (1 person), Hodgkin's disease (2 people), lymphoma (4 people), bladder carcinoma (3 people), testicular carcinoma (70 people)</p> <p>Chemotherapy regimens: doxorubicin hydrochloride and cyclophosphamide (1 person), nitrogen mustard, vincristine, prednisone and procarbazine (2 people), cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisone (4 people), cisplatin, doxorubicin hydrochloride and 5-fluorouracil (3 people), cisplatin, vinblastine and bleomycin (45 people), cisplatin, vinblastine, bleomycin and doxorubicin hydrochloride (25 people). No information on doses reported</p> <p>Chemotherapy emetogenicity: high</p>
Interventions	<p>Nabilone 2 mg, orally every 6 hours, n = 100</p> <p>Prochlorperazine 10 mg, orally every 6 hours, n = 100</p>
Outcomes	Episodes of nausea and vomiting during 24 hours of therapy; frequency of vomiting; withdrawal due to adverse effects; withdrawal due to early death and change of chemotherapy; episodes of 'feeling high', depression, hallucination, paranoia, hypotension
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Low risk	"Identical capsules used"
Incomplete outcome data (attrition bias) All outcomes	Low risk	80/100 (80%) participants received nabilone, 80/100 (80%) participants received prochlorperazine
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as "double-blind", identical capsules used
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind", identical capsules used

Frytak 1979

Methods	Randomised, double-blind, parallel group trial
Participants	<p>116 people, median age = 61 years. All cannabis naive. THC n = 38 (22 men/16 women), prochlorperazine n = 41 (21 men/20 women), placebo n = 37 (27 men/10 women)</p> <p>Tumour types: colorectal cancer (28 people), gastric cancer (7 people), liver cancer (2 people), miscellaneous (1 person), gastric surgery (5 people), hepatic metastasis (20 people)</p> <p>Chemotherapy regimens: 5-fluorouracil and semustine or 5-fluorouracil and semustine plus triazinate, razoxane, doxorubicin or vincristine. 5-fluorouracil 300-350 mg/m² IV for 5 days. Semustine 110-175 mg/m² day 1 only</p> <p>Chemotherapy emetogenicity: moderate</p>
Interventions	<p>Dronabinol 15 mg on day 1, 2 hours prior to chemotherapy, then 2 and 8 hours after initiation of chemotherapy. Then 3 times daily x 3 days orally, n = 38</p> <p>Prochlorperazine 10 mg on day 1, 2 hours prior to chemotherapy, then 2 and 8 hours after initiation of chemotherapy. Then 3 times daily x 3 days orally, n = 41</p> <p>Placebo n = 37</p>
Outcomes	Episodes of nausea and vomiting during 24 hours, sedation, feeling high; withdrawal due to intolerable central nervous system toxicity or excessive vomiting
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Table of random numbers
Allocation concealment (selection bias)	Low risk	Drugs dispensed in individual packets identified by code number
Incomplete outcome data (attrition bias) All outcomes	Low risk	Only 1/117 (0.8%) participants withdrew. After day 1, 10/38 (26%) participants withdrew in THC group, 5/41 (12%) participants withdrew in prochlorperazine group, 3/37 (8%) participants withdrew in placebo group
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Low risk	Groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical opaque gelatin capsules"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind"

George 1983

Methods	Randomized double-blind 2-period cross-over study
Participants	<p>20 people, mean age 54.1 years</p> <p>Tumour type: advanced gynaecological cancer who vomited during the first chemotherapy treatment</p> <p>Chemotherapy regimen: cis-platinum (50 mg/m²) with hydration. Vomited during the first treatment. Doxorubicin (40 mg/m²), cyclophosphamide (600 mg/m²) and cis-platinum (11 people); cyclophosphamide 600 mg and cis-platinum (3 people); cis-platinum (6 people)</p> <p>Chemotherapy emetogenicity: high</p>
Interventions	<p>Nabilone 1 mg 24 hours before chemotherapy then 1 mg 3 times daily orally</p> <p>Chlorpromazine 12.5 mg IM before chemotherapy with additional dose if requested</p>
Outcomes	Number of vomiting episodes in 24 hours, participant preference, adverse events
Notes	Translated from French

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly allocated by lottery
Allocation concealment (selection bias)	Low risk	Identical placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	All people were included in the analysis
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Low risk	There was no evident difference caused by the order of administration of the drugs
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical placebo, double-dummy tablets used
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as double-blind

Gralla 1984

Methods	Randomised, double-blinded parallel group trial
Participants	31 people (23 men/ 5 women). THC n = 15 (13 men/2 women), aged 39-72 years (median = 58 years); metoclopramide n = 16 (11 men/5 women), aged 45-70 years (median = 58 years)

Gralla 1984 (Continued)

Tumour types: bronchogenic carcinoma (12 people), oesophageal carcinoma (2 people), head and neck carcinoma head and neck carcinoma (1 person)

Chemotherapy regimens: all receiving first course of cisplatin 120 mg/m² IV

Chemotherapy emetogenicity: high

Interventions	Dronabinol 10 mg/m ² 1.5 hours prior to chemotherapy, then at 1.5, 4.5, 7.5 and 10.5 hours after chemotherapy orally, n = 15 Metoclopramide, 2 mg/kg 30 minutes prior to chemotherapy, then 1.5, 3.5, 5.5 and 8.5 hours after chemotherapy IV, n = 16
Outcomes	Episodes of nausea and vomiting during 24 hours, sedation, dizziness, orthostatic hypotension, feeling high
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Paired design in which one patient in every pair was randomly assigned to each treatment"
Allocation concealment (selection bias)	Low risk	"Identical vials and capsules used"
Incomplete outcome data (attrition bias) All outcomes	Low risk	15/15 (100%) participants received THC, 15/16 (94%) participants received metoclopramide
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical vials and capsules used"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind"

Herman 1979

Methods	Randomised, double-blinded, 2-period cross-over study
Participants	152 people (126 men/26 women) aged 15-74 years (median = 33 years) Tumour type: testicular carcinoma (70 people), non-Hodgkin's disease (12 people), Hodgkin's disease (11 people) Chemotherapy regimen: cisplatin daily for 5 days, vinblastine and bleomycin (70 people); cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP 12 people); nitrogen mustard

Herman 1979 (Continued)

(mechlorethamine?), vincristine, procarbazine and prednisone (MOPP 11 people); other regimens included dactinomycin, dacarbazine, 5-fluorouracil, melphalan and nitrosourea compounds. No information on doses reported

Chemotherapy emetogenicity: high

Interventions	Nabilone 2 mg, every 8 hours orally, n = 152 Prochlorperazine 10 mg, every 8 hours orally, n = 152
Outcomes	Episodes of nausea and vomiting daily during chemotherapy; withdrawal due to adverse effects; episodes of somnolence, dizziness, depression, euphoria, preference
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Low risk	"Drugs packaged in identical containers marked only with a number code"
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	113/152 (74%) participants received nabilone, 113/152 (74%) participants received prochlorperazine
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical containers marked only with a number code"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind" and "identical containers marked only with a number code"

Johansson 1982

Methods	Randomised, double-blind, 2-period cross-over study
Participants	27 people aged 18-70 years Tumour types: cervical cancer (2 people), cancer of fallopian tubes (2 people), ovarian cancer (13 people), testicular cancer (2 people), head and neck cancer (1 person), bronchus cancer (1 person), histiocytoma (1 person), fibrosarcoma (1 person), oligodendroma (1 person), lymphoma (2 people) Chemotherapy regimens: doxorubicin 40 mg/m ² , cyclophosphamide 500 mg/m ² and cisplatinum 50 mg/m ² (11 people) in combination with vinblastine, vincristine or ftorafur (tegfur-uracil). Cyclophosphamide 750-1000 mg/m ² and cisplatinum 75 mg/m ² when given as sole agents

Johansson 1982 (Continued)

Chemotherapy emetogenicity: high

Interventions	Nabilone 2 mg twice daily x 4 days orally, n = 27 Prochlorperazine 10 mg twice daily x 4 days orally, n = 27
Outcomes	Episodes of nausea and vomiting assessed daily and reported for follow-up at end of anti-emetic therapy; withdrawal due to lack of efficacy; withdrawal due to hypotension, vertigo and headache; participant preference; episodes of drowsiness, dizziness, depression, hypotension
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	18/27 (67%) participants received nabilone, 18/27 (67%) participants received prochlorperazine
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as "double-blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind"

Jones 1982

Methods	Prospective, randomised, double-blind, 2-period cross-over trial
Participants	54 people; aged 20-37 years (n = 9), 38-57 years (n = 23), > 58 years (n = 22) Tumour types: breast cancer (15 people), lymphoma (12 people), ovarian cancer (8 people), lung cancer (7 people), melanoma (3 people), testicular cancer (2 people), miscellaneous (7 people) Chemotherapy regimens: adriamycin-based regimens (25 people), cisplatin-based regimens (14 people), other combinations (12 people). No information on doses reported Chemotherapy emetogenicity: high
Interventions	Nabilone 2 mg every 12 hours orally, n = 54

Jones 1982 (Continued)

Placebo, n = 54

Outcomes	Episodes of nausea and vomiting unclear time period of results unclear; withdrawal due to severe nausea and vomiting; episodes of drowsiness, euphoria, hallucination, hypotension
----------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Notes	
-------	--

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	24/54 (44%) participants received nabilone, 24/54 (44%) participants received placebo
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as "double-blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind"

Kleinman 1983

Methods	Randomised, double-blind, 4-period cross-over study
Participants	16 people (9 men/7 women) aged 18-53 years (median = 38 years) Tumour types: not reported Chemotherapy regimens: "Cancer chemotherapy known to cause acute gastrointestinal toxicity" Chemotherapy emetogenicity: unable to classify
Interventions	Prochlorperazine 10 mg + dronabinol 15 mg x 2 courses orally, n = 16 Prochlorperazine + placebo orally, n = 16
Outcomes	Episodes of nausea and vomiting 24 hours after chemotherapy, euphoria, sedation
Notes	

Kleinman 1983 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	28/32 (87.5%) participants received prochlorperazine + THC, 24/32 (75%) participants received prochlorperazine + placebo (overall 52/64 (81%) participants received either of the 2 courses)
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as "double-blind" and "identical capsules used"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind and identical capsules used"

Kluin-Neleman 1979

Methods	Randomised, double-blind, 2-period cross-over study
Participants	11 people (10 men/1 woman) aged 21-53 years Tumour types: Hodgkin's or non-Hodgkin's lymphoma Chemotherapy regimens: mitoxine 6 mg/m ² (maximum 10 mg), vincristine 1.4 mg/m ² (maximum 2 mg) IV on days 1 and 8. Procarbazine 100 mg/m ² and prednisone 40 mg/m ² oral days 1-14 for 6 cycles with intervals of 2 weeks Chemotherapy emetogenicity: high
Interventions	Dronabinol 10 mg/m ² orally, n = 11 Placebo, n = 11
Outcomes	Episodes of nausea and vomiting at end of day of therapy, feeling high, dizziness, hallucinations
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
------	--------------------	-----------------------

Kluin-Neleman 1979 (Continued)

Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	17 participants received THC, 11 participants received placebo
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Washout period 2 weeks. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical gelatin capsules were used"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind" and "identical gelatin capsules used"

Lane 1991

Methods	Randomised, double-blind, parallel group study
Participants	<p>Dronabinol n = 21 (10 men/11 women) aged 20-68 years (median = 47 years), prochlorperazine n = 21 (10 men/11 women) aged 22-64 years (median = 49 years), dronabinol plus prochlorperazine n = 20 (9 men/11 women) aged 25-65 years (median = 55.5 years). Total n = 62 (29 men/33 women) aged 20-68 years (median = 52 years)</p> <p>All cannabis naive</p> <p>Tumour types: breast cancer (24 people), colon cancer (3 people), lung cancer (8 people), lymphoma (17 people), miscellaneous (10 people)</p> <p>Chemotherapy regimens: cyclophosphamide and doxorubicin (26 people), 5-fluorouracil (14 people), vincristine (13 people), etoposide (10 people), No information on doses reported. 48/62 participants received chemotherapy with high emetogenic potential</p> <p>Chemotherapy emetogenicity: unable to classify</p>
Interventions	<p>Dronabinol 10 mg every 6 hours orally, n = 21</p> <p>Prochlorperazine 10 mg every 6 hours orally, n = 21</p> <p>Dronabinol 10 mg + prochlorperazine 10 mg orally, n = 20</p>
Outcomes	Episodes of nausea and vomiting during chemotherapy treatment; withdrawal due to adverse effects; episodes of somnolence, dizziness, paranoid reaction, depression
Notes	

Risk of bias
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (Review)

Lane 1991 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	17/21 (81%) participants received dronabinol, 20/21 (95%) participants received prochlorperazine, 17/20 (85%) participants received dronabinol + prochlorperazine
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Low risk	Groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as "double-blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind"

Levitt 1982

Methods	Randomised, double-blind, 2-period cross-over study	
Participants	58 people aged 17-78 years Tumour types: lung cancer (21 people), ovarian cancer (11 people), breast cancer (10 people), other cancers (16 people) Chemotherapy regimens: combinations of doxorubicin, bleomycin, cisplatin, cyclophosphamide, dactinomycin, melphalan, mitomycin C, methotrexate, vincristine, etoposide, 5-fluorouracil. No information on doses reported Chemotherapy emetogenicity: unable to classify	
Interventions	Nabilone, n = 58 Placebo, n = 58	
Outcomes	Episodes of nausea and vomiting time of assessment unclear, frequency and severity of nausea, withdrawal due to lack of efficacy, adverse effects, episodes of drowsiness	
Notes	Dose and duration not reported	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported

Levitt 1982 (Continued)

Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	36/58 (62%) participants received nabilone, 36/58 (62%) participants received placebo
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as "double-blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind"

McCabe 1988

Methods	Randomised, 2-period cross-over trial
Participants	<p>36 (9 men/27 women) aged 18-69 years (median = 48 years)</p> <p>Tumour types: breast cancer (11 people), haematological malignancies (9 people), sarcomas (6 people), gastrointestinal malignancies (5 people), melanoma (2 people), ovarian cancer (2 people), testicular cancer (1 person)</p> <p>Chemotherapy regimens: doxorubicin (13 people), cyclophosphamide, methotrexate and 5-fluorouracil (7 people), nitrogen mustard, vincristine, procarbazine and prednisone (7 people), platinum combinations (4 people), DTIC (2 people), 5-fluorouracil combinations (2 people), 5-azacytidine (1 person). No information on doses reported</p> <p>Chemotherapy emetogenicity: moderate to high</p>
Interventions	<p>Dronabinol 15 mg/m² 1 hour prior to chemotherapy, then every 4 hours for 24 hours after chemotherapy orally, n = 36</p> <p>Prochlorperazine 10 mg 1 hour prior to chemotherapy, then every 4 hours for 24 hours after chemotherapy orally, n = 36</p>
Outcomes	Episodes of nausea and vomiting during 24 hours, feeling high, dizziness, dysphoria, hallucination, paranoia
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported

McCabe 1988 (Continued)

Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	All people were analysed
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	High risk	"Blinding not achieved"
Blinding of outcome assessment (detection bias) All outcomes	High risk	Study not blinded

Niiranen 1985

Methods	Randomised, double-blind, 2-period cross-over study
Participants	32 people (20 men/4 women) aged 48-78 years, mean = 61 years Tumour type: lung cancer Chemotherapy regimen: cyclophosphamide 1.2 g/m ² day 1, etoposide 150 mg/m ² IV day 1, 250 mg/m ² orally day 3, and vincristine 1.3 mg/m ² days 1 and 8 (5 people); cyclophosphamide 400 mg/m ² , adriamycin 40 mg/m ² , cisplatin 40 mg/m ² every 28 days (8 people); cisplatin 90 mg/m ² day 1 and vindesine 3 mg/m ² 5 x weekly then twice monthly every 28 days (2 people); cisplatin 90 mg/m ² day 1 and etoposide 50 mg/m ² days 1-5 every 28 days (9 people); cisplatin 60 mg/m ² day 1 and etoposide 150 mg/m ² IV day 1 and 200 mg/m ² orally day 3 every 28 days (1 person) Chemotherapy emetogenicity: high
Interventions	Nabilone 1 mg orally night before chemotherapy, 1 hour before chemotherapy and every 12 hours up to 24 hours as required orally, n = 32 Prochlorperazine 7.5 mg orally night before chemotherapy, 1 hour before chemotherapy and every 12 hours up to 24 hours as required orally, n = 32
Outcomes	Episodes, frequency and severity of nausea and vomiting at 24 hours; withdrawal due to adverse effects; participant preference; episodes of drowsiness, hallucination, hypotension
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported

Niiranen 1985 (Continued)

Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	24/32 (75%) participants received nabilone, 24/32 (75%) participants received prochlorperazine
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical appearing capsules used"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind" and "identical appearing capsules used"

Orr 1981

Methods	Randomised double-blind 2-period cross-over
Participants	79 people (28 men/51 women) aged 22-71 years, mean = 46 years Tumour type: variety of neoplasms Chemotherapy regimen: doxorubicin, cyclophosphamide, 5-fluorouracil (with methotrexate), nitrogen mustard, imidazole carboxamide, nitrosaura and cytosine arabinoside. No information on doses reported Chemotherapy emetogenicity: high (5-fluorouracil + methotrexate low risk but only 3/55 people)
Interventions	Dronabinol 7 mg/m ² every 4 hours x 4 doses orally, n = 79 Prochlorperazine 7 mg every 4 hours x 4 doses orally, n = 79
Outcomes	Nausea 24 hours post treatment and adverse events
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias)	High risk	55/79 (69%) participants in both groups analysed

Orr 1981 (Continued)

All outcomes

Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical capsule used"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	States "double-blind"

Pomeroy 1986

Methods	Randomised, double-blind parallel group trial
Participants	<p>38 people (23 men/15 women) aged 21-66 years (median = 42 years)</p> <p>Tumour types: ovarian cancer (11 people), testicular cancer (9 people), bronchus carcinoma (8 people), non-Hodgkin's lymphoma (3 people), Hodgkin's disease (2 people), sarcoma (2 people), breast cancer (1 person), melanoma (1 person), nephroblastoma (1 person)</p> <p>Chemotherapy regimens: cisplatin (10 people); cisplatin and treosulphan (7 people); cisplatin, vincristine, methotrexate and bleomycin (4 people); cisplatin, actinomycin D and etoposide (2 people); cisplatin, vinblastine and bleomycin (2 people); cisplatin and vindesine (1 person); adriamycin, bleomycin, vincristine and DTIC (2 people); adriamycin, vincristine and cyclophosphamide (2 people); adriamycin, vincristine, cyclophosphamide and prednisone (2 people); adriamycin, vincristine and etoposide (1 person); ifosfamide (2 people); vincristine, methotrexate and 5-fluorouracil (1 person); vindesine, DTIC and 1-(2-chloroethyl)3-cyclohexyl-1-nitrosourea (CCNU) (1 person). No information on doses reported</p> <p>Chemotherapy emetogenicity: high</p>
Interventions	<p>Nabilone 1 mg 3 times daily x 2 cycles orally, n = 19</p> <p>Domperidone 20 mg 3 times daily x 2 cycles orally, n = 19</p>
Outcomes	Episodes of vomiting daily, withdrawal due to adverse effects, lack of efficacy, episodes of drowsiness, dizziness, hypotension, euphoria
Notes	2 cycles of chemotherapy evaluated

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported

Pomeroy 1986 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	32/38 (84%) participants received nabilone, 33/38 (87%) participants received domperidone
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical capsules used"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind" and "identical capsules used"

Sallan 1975a

Methods	Randomised, double-blind, 2-period cross-over study	
Participants	22 people (10 men/12 women) aged 18-76 years (median = 29.5 years) Tumour types: variety of neoplasms Chemotherapy regimen: adriamycin, 5-azacytidine, nitrogen mustard, imidazole carboxamide, procarbazine, high-dose cyclophosphamide or high-dose methotrexate or combinations. No information on doses reported Chemotherapy emetogenicity: unable to classify	
Interventions	Dronabinol 15 mg, later changed to 10 mg/m ² , every 4 hours x 3 doses orally, n = 33 Placebo, n = 33	
Outcomes	Episodes of nausea and vomiting on day after treatment, withdrawal due to adverse effects, episodes of feeling high, somnolence, paranoia, hallucination	
Notes		

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	20/33 (61%) participants received THC, 22/33 (67%) participants received placebo

Sallan 1975a (Continued)

Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical gelatin capsules used"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind" and "identical gelatin capsules used"

Steele 1980

Methods	Randomised, double-blind, 2-period cross-over study
Participants	55 people aged 19-65 years Tumour types: not reported Chemotherapy regimen: high-dose <i>cis</i> -dichlorodiammineplatinum 120 mg/m ² ± vindesine 3 mg/m ² every 4-6 weeks; low-dose <i>cis</i> -dichlorodiammineplatinum 60 mg/m ² ± vindesine 3 mg/m ² , every 4-6 weeks; low-dose <i>cis</i> -dichlorodiammineplatinum 60 mg/m ² ± adriamycin 45 mg/m ² every 3-4 weeks; mechlorethamine 6 mg/m ² + vincristine 1.4 mg/m ² + procarbazine orally x 14 days 100 mg/m ² every 4 weeks days 1-8; streptozotocin 500 mg/m ² every week; actinomycin D 1 mg/m ² ± vinblastine 4 mg/m ² + chlorambucil orally x 14 days 4 mg/m ² or 0.15 mg/kg every 3-4 weeks; DTIC 800 mg/m ² ± cyclophosphamide orally x 14 days 100 mg/m ² every 4 weeks. All drugs IV unless otherwise stated Chemotherapy emetogenicity: high
Interventions	Nabilone 2 mg every 12 hours x 3-5 doses orally, n = 55 Prochlorperazine 10 mg every 12 hours x 3-5 doses orally, n = 55
Outcomes	Episodes of nausea and vomiting during 24 hours; withdrawal due to adverse effects; lack of efficacy, episodes of somnolence, dizziness, feeling high, postural hypotension, dysphoria, hallucination
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	37/55 (67%) participants received nabilone, 37/55 (67%) participants received prochlorperazine

Steele 1980 (Continued)

Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as "double-blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind"

Ungerleider 1982

Methods	Randomised, double-blind, 2-period cross-over study
Participants	214 people (107 men/107 women) aged 18-82 years (median = 47 years) Tumour types: "wide variety of neoplasms" Chemotherapy regimens: antibiotics (70 people), nitrosoureas (21 people), alkylating agents (119 people), antimetabolites (82 people), vinca-alkaloids (60 people), hormones (13 people), miscellaneous (33 people) and combinations. Rated as high for 66% of people, moderate for 27% of people or low for 7% of people emetic potential Chemotherapy emetogenicity: unable to classify - unknown combinations
Interventions	Dronabinol 7.5 mg for < 1.4/m ² , 10 mg for 1.4-1.8 m ² or 12.5 mg for > 1.8 m ² orally, n = 214 Prochlorperazine 10 mg 1 hour prior to chemotherapy, then every 4 hours x 4 doses per day x all chemotherapy days orally, n = 214
Outcomes	Episodes of nausea and vomiting during 24 hours; withdrawal due to adverse effects; episodes of sedation, depression, feeling high
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Table of random numbers
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	172/214 (80%) participants received THC, 181/214 (85%) received prochlorperazine
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome

Ungerleider 1982 (Continued)

Other bias	Low risk	Washout period 1-3 weeks. Paired analysis was performed. Groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as "double-blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind"

Wada 1982

Methods	Randomised, double-blind, 2-period cross-over trial
Participants	<p>114 people (47 men/67 women) aged 18-81 years (median = 57 years)</p> <p>Tumour types: lung cancer (23 people), breast cancer (18 people), ovarian cancer (16 people), lymphoma (including Hodgkin's) (12 people), colonic cancer (7 people), prostatic cancer (5 people), adenocarcinoma (5 people), bladder cancer (3 people), melanoma (3 people), pancreatic cancer (3 people), oesophageal cancer (3 people), stomach cancer (3 people), sarcoma (2 people), testicular cancer (2 people), others (9 people)</p> <p>Chemotherapy regimens: adriamycin (66 people), carmustine (2 people), bleomycin (7 people), cisplatin (40 people), cytoxan (46 people), dactinomycin (1 person), DTIC (7 people), 5-fluorouracil (29 people), mustine (4 people), MCCNU (6 people), melphalan (1 person), methotrexate (14 people), mitomycin (17 person), procarbazine (7 people), streptozotocin (1 person), tamoxifen (1 person), vinblastine (5 person), vincristine (16 people), VP-16 (1 person)</p>
Interventions	<p>Nabilone 2 mg night prior and 1-3 hours before chemotherapy and then every 12 hours orally, n = 114</p> <p>Placebo, n = 114</p>
Outcomes	Episodes of nausea and vomiting during 24 hours; withdrawal due to adverse effects; lack of efficacy; progressive disease; death; participant preference; episodes of dizziness, drowsiness, euphoria, dysphoria, hypotension, hallucination
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	84/114 (74%) participants completed both the courses, 92/114 (81%) participants were evaluable for efficacy
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome

Wada 1982 (Continued)

Other bias	Unclear risk	Assumed washout period sufficient. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as "double-blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double-blind"

DTIC: 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide; HN2: ; IM: intramuscular; IV: intravenous; MCCNU: methyl lomustine; n: number; THC: delta-9-tetrahydrocannabinol.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Aapro 1981	Not a primary study - editorial
Allan 1987	Not a primary study - review
Anderson 1981	Not a primary study - review
Artim 1983	Participants received chemotherapy and radiotherapy
Bateman 1982	Not a primary study - letter
Ben 2006	Not a primary study - review
Biedrzycki 2007	Not a primary study - conference presentation
Broder 1982	Lacks data - abstract of preliminary findings, participant age and characteristics not reported
Carey 1983	Not a primary study - review
Chan 1987	Randomised controlled trial involving children
Chang 1979b	Duplicate of Chang 1979a
Citron 1985	Cross route comparison of intramuscular versus oral cannabinoid
Cocchetto 1981	Not a primary study - review
Colls 1980a	Letter - lacks detail on study methods, participant groups, control intervention and results
Colls 1980b	Did not report data for primary outcome, measurement of nausea and vomiting using a non-validated measure. No details on participants reported
Cone 1982	Not randomised - single-arm study
Costa 2007	Not a primary study - review
Cotter 2009	Not a primary study - review

Study	Reason for exclusion
Cronin 1981	Not randomised - single-arm cross-over study
Croxford 2003	Not a primary study - review
Cunningham 1985	Control group was cannabinoid monotherapy and not conventional anti-emetic
Cunningham 1988	Sub-therapeutic dose of prochlorperazine used
Dalzell 1986	Randomised controlled trial involving children
Darmani 2010	Not a primary study - review
Davis 2007	Not a primary study - review
Davis 2008	Not a primary study - review
Devine 1987	Not randomised - single-arm cross-over study
Dodds 1985	Not a primary study - review from thesis
Dow 1984	Not a primary study - letter
Duran 2010	Not an approved formulation of delta-9-tetrahydrocannabinol
Ekert 1979	Randomised controlled trial involved children not adults
Ettinger 2007	Not a primary study - clinical practice guidelines
Feyer 2011	Not a primary study - review
Fiore 1984	Not a primary study - review
Fox 1979	Not a primary study - letter
Galal 2009	Not a primary study - review
Gallego 1984	Not a primary study - review
Gerhartz 1983	Not randomised - single-arm study
Gerra 2010	Not a primary study - review
Goodman 1997	Not a primary study - review
Gorter 1999	Not randomised
Grunberg 1989	Not a primary study - review
Guzman 2003	Not a primary study - review
Heim 1984	Evaluates a non-approved formulation of delta-9-tetrahydrocannabinol
Herrstedt 1998	Not a primary study - review
Herrstedt 2008	Not a primary study - review

Study	Reason for exclusion
Higi 1982	Pilot study
Hiller 1984	Not a primary study - review
Hutcheon 1983	Evaluates a non-approved formulation of delta-9-tetrahydrocannabinol
Jordan 2007	Not a primary study - review
Jordan 2011	Not a primary study - review guideline
Kearsley 1985	Not a primary study - review
Kenny 1982	Non-randomised single-arm study
Kluin-Nelemans 1981a	Duplicate to included
Kluin-Nelemans 1981b	Not randomised. Abstract with scant details of methods reported
Krasnow 1991	Not a primary study - review
Kreutz 2007	Not a primary study - review
Lane 1989	Duplicate Lane 1991
Lane 1990	Duplicate data. Single-centre study included in Lane 1991
Laszlo 1982	Not a primary study - review
Levitt 1981	Evaluates ophthalmological outcomes. Nausea and vomiting not evaluated
Levitt 1984	Cross-route comparison of oral versus smoked cannabis
Lohr 2008	Not a primary study - review
Long 1982	Preliminary data presented
Machado 2008	Not a primary study - systematic review and meta-analysis
Mechoulam 1978	Not a primary study - drug development
Mechoulam 1999	Not a primary study - review
Mechoulam 2001	Not a primary study - review
Meiri 2007	Not acute nausea and vomiting but evaluating delayed nausea and vomiting
Murakami 1986	Not a primary study - review
Musty 2001	Not a primary study - review
Nagy 1978	Scanty data in an abstract - no extractable data
Navari 2009a	Not a primary study - review
Navari 2009b	Not a primary study - review

Study	Reason for exclusion
Niederle 1986	Evaluates a non-eligible anti-emetic (alizapride)
Niiranen 1987	Control group was cannabinoid monotherapy and not conventional anti-emetic
Nyman 1982	Not a primary study - review
Orr 1980	Duplicate of Orr 1981
Penta 1981	Not a primary study - review
Perwitasari 2011	Not a primary study - review
Phillips 2010	Not a primary study - review
Plasse 1991	Not a primary study - expert opinion
Porta 2002	Not a primary study - review
Poster 1981	Not a primary study - review
Reynolds 2002	Not a primary study - letter
Sallan 1975b	Duplicate study of Sallan 1975a
Sallan 1980	Participants aged 9-70 years; number or percent of children included not reported
Schuette 1985	Duplicate study reported in Niederle 1986
Sheidler 1984	Evaluates a non-approved formulation of delta-9-tetrahydrocannabinol
Slatkin 2007	Not a primary study - review
Smith 2007	Not a primary study - review
Stambaugh 1982	Cross-route comparison of intramuscular versus oral cannabinoid
Stambaugh 1984	Evaluates a non-approved formulation of delta-9-tetrahydrocannabinol
Steele 1979	Duplicate study reported in Steele 1980
Stewart 1990	Not a primary study - review
Stuart 1982	Not randomised - single-arm study
Stuart-Harris 1983	Not randomised
Sweet 1980	Not a primary study - letter
Toth 2008	Not a primary study - review
Tramer 2001	Not a primary study - review
Ungerleider 1985	Sub-group analysis of study reported in Ungerleider 1982
Venner 1986	Preliminary results - ongoing study

Study	Reason for exclusion
Vincent 1983	Not a primary study - review
Voth 1997	Not a primary study - review
Wang 2008	Not a primary study - review
Ward 1985	Not a primary study - drug evaluation
Ware 2008	Not a primary study - review
Zuardi 2008	Not a primary study - review

Characteristics of studies awaiting assessment *[ordered by study ID]*

Citron 1983

Methods	Double-blind, randomised, crossover study
Participants	People receiving chemotherapy
Interventions	IM levonantradol, a synthetic cannabinoid, given at a dose of 1 mg every 4 hours versus oral delta-9-tetrahydrocannabinol (THC) given at a dose of 15 mg every 4 hours
Outcomes	Nausea, emetic episodes
Notes	

Earhart 1983

Methods	RCT
Participants	Cancer patients receiving cisplatin chemotherapy
Interventions	Evonantradol versus prochlorperazine as parenteral antiemetics
Outcomes	Nausea and vomiting
Notes	

Jhangiani 2005

Methods	Double-blind, placebo-controlled study
Participants	Patients receiving moderately to highly emetogenic chemotherapy
Interventions	Dronabinol alone or in combination with ondansetron versus ondansetron alone
Outcomes	Nausea and vomiting intensity

Jhangiani 2005 (Continued)

Notes

Neidhart 1981


Methods	A prospective, randomized and double-blinded trial
Participants	All patients are receiving chemotherapeutic agents known to induce severe vomiting
Interventions	Effects of delta-9-tetrahydrocannabinol and haloperidol
Outcomes	Nausea and vomiting
Notes	

DATA AND ANALYSES
Comparison 1. Cannabinoid versus placebo


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Absence of nausea	2	96	Risk Ratio (IV, Random, 95% CI)	2.0 [0.19, 20.97]
2 Absence of vomiting	3	168	Risk Ratio (IV, Random, 95% CI)	5.69 [2.56, 12.64]
2.1 Nabilone	1	72	Risk Ratio (IV, Random, 95% CI)	7.25 [2.84, 18.52]
2.2 Dronabinol	2	96	Risk Ratio (IV, Random, 95% CI)	3.0 [0.65, 13.76]
3 Absence of nausea and vomiting	3	288	Risk Ratio (IV, Random, 95% CI)	2.86 [1.76, 4.65]
3.1 Cannabis naive	1	75	Risk Ratio (IV, Random, 95% CI)	2.23 [1.04, 4.78]
3.2 Prior cannabis use	2	213	Risk Ratio (IV, Random, 95% CI)	3.40 [1.80, 6.39]
4 Depression	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
5 Dysphoria	2	96	Risk Ratio (IV, Random, 95% CI)	9.00 [0.50, 160.59]
6 'Feeling high'	3	137	Risk Ratio (IV, Random, 95% CI)	31.10 [6.37, 151.85]
7 Paranoia	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
8 Sedation	2	139	Risk Ratio (IV, Random, 95% CI)	4.47 [0.35, 57.81]
9 Participant preference	2	256	Risk Ratio (IV, Random, 95% CI)	4.82 [1.74, 13.36]
10 Withdrawal for any reason	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
11 Withdrawal due to adverse event	2	276	Risk Ratio (IV, Random, 95% CI)	6.85 [1.96, 23.99]
12 Withdrawal due to lack of efficacy	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only


Analysis 1.1. Comparison 1 Cannabinoid versus placebo, Outcome 1 Absence of nausea.




Analysis 1.2. Comparison 1 Cannabinoid versus placebo, Outcome 2 Absence of vomiting.




Analysis 1.3. Comparison 1 Cannabinoid versus placebo, Outcome 3 Absence of nausea and vomiting.




Analysis 1.4. Comparison 1 Cannabinoid versus placebo, Outcome 4 Depression.




Analysis 1.5. Comparison 1 Cannabinoid versus placebo, Outcome 5 Dysphoria.




Analysis 1.6. Comparison 1 Cannabinoid versus placebo, Outcome 6 'Feeling high'.




Analysis 1.7. Comparison 1 Cannabinoid versus placebo, Outcome 7 Paranoia.




Analysis 1.8. Comparison 1 Cannabinoid versus placebo, Outcome 8 Sedation.




Analysis 1.9. Comparison 1 Cannabinoid versus placebo, Outcome 9 Participant preference.




Analysis 1.10. Comparison 1 Cannabinoid versus placebo, Outcome 10 Withdrawal for any reason.



Analysis 1.11. Comparison 1 Cannabinoid versus placebo, Outcome 11 Withdrawal due to adverse event.



Analysis 1.12. Comparison 1 Cannabinoid versus placebo, Outcome 12 Withdrawal due to lack of efficacy.



Comparison 2. Cannabinoid versus other anti-emetic agent


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Absence of nausea	5	258	Risk Ratio (IV, Random, 95% CI)	1.46 [0.67, 3.15]
1.1 Prochlorperazine	5	258	Risk Ratio (IV, Random, 95% CI)	1.46 [0.67, 3.15]
2 Absence of nausea (subgroup analysis 2)	5		Risk Ratio (IV, Random, 95% CI)	Subtotals only
2.1 Nabilone	3	141	Risk Ratio (IV, Random, 95% CI)	1.41 [0.33, 6.03]
2.2 Dronabinol	2	117	Risk Ratio (IV, Random, 95% CI)	2.38 [0.21, 26.91]
3 Absence of vomiting	4	209	Risk Ratio (IV, Random, 95% CI)	1.11 [0.86, 1.44]
3.1 Prochlorperazine	4	209	Risk Ratio (IV, Random, 95% CI)	1.11 [0.86, 1.44]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4 Absence of vomiting (subgroup analysis 2)	4		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4.1 Nabilone	2	93	Risk Ratio (IV, Random, 95% CI)	1.55 [0.39, 6.24]
4.2 Dronabinol	2	116	Risk Ratio (IV, Random, 95% CI)	1.05 [0.64, 1.71]
5 Absence of nausea and vomiting	4	414	Risk Ratio (IV, Random, 95% CI)	2.00 [0.74, 5.38]
5.1 Prochlorperazine	4	414	Risk Ratio (IV, Random, 95% CI)	2.00 [0.74, 5.38]
6 Absence of nausea and vomiting (subgroup analysis 1)	4		Risk Ratio (IV, Random, 95% CI)	Subtotals only
6.1 Cannabis naive	2	116	Risk Ratio (IV, Random, 95% CI)	1.10 [0.70, 1.72]
6.2 Prior cannabis use	2	298	Risk Ratio (IV, Random, 95% CI)	17.98 [2.44, 132.43]
7 Absence of nausea and vomiting (subgroup analysis 2)	4		Risk Ratio (IV, Random, 95% CI)	Subtotals only
7.1 Nabilone	1	226	Risk Ratio (IV, Random, 95% CI)	17.0 [0.99, 291.06]
7.2 Dronabinol	3	188	Risk Ratio (IV, Random, 95% CI)	1.44 [0.62, 3.31]
8 Dizziness	9	743	Risk Ratio (IV, Random, 95% CI)	2.54 [1.91, 3.37]
8.1 Domperidone	1	38	Risk Ratio (IV, Random, 95% CI)	2.75 [1.06, 7.12]
8.2 Prochlorperazine	7	675	Risk Ratio (IV, Random, 95% CI)	2.36 [1.82, 3.07]
8.3 Metoclopramide	1	30	Risk Ratio (IV, Random, 95% CI)	12.0 [1.78, 81.06]
9 Dysphoria	3	192	Risk Ratio (IV, Random, 95% CI)	7.17 [1.33, 38.84]
9.1 Prochlorperazine	3	192	Risk Ratio (IV, Random, 95% CI)	7.17 [1.33, 38.84]
10 Euphoria	4	358	Risk Ratio (IV, Random, 95% CI)	8.89 [2.05, 38.63]
10.1 Domperidone	1	38	Risk Ratio (IV, Random, 95% CI)	5.0 [0.26, 97.70]
10.2 Prochlorperazine	2	280	Risk Ratio (IV, Random, 95% CI)	17.97 [2.42, 133.37]
10.3 Chlorpromazine	1	40	Risk Ratio (IV, Random, 95% CI)	3.0 [0.13, 69.52]
11 'Feeling high'	5	419	Risk Ratio (IV, Random, 95% CI)	5.90 [3.42, 10.17]
11.1 Prochlorperazine	4	389	Risk Ratio (IV, Random, 95% CI)	6.18 [3.52, 10.85]
11.2 Metoclopramide	1	30	Risk Ratio (IV, Random, 95% CI)	3.0 [0.35, 25.68]
12 Hallucinations	2	144	Risk Ratio (IV, Random, 95% CI)	5.39 [0.66, 43.68]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
12.1 Prochlorperazine	2	144	Risk Ratio (IV, Random, 95% CI)	5.39 [0.66, 43.68]
13 Postural hypotension	6	413	Risk Ratio (IV, Random, 95% CI)	2.40 [0.88, 6.53]
13.1 Domperidone	1	38	Risk Ratio (IV, Random, 95% CI)	4.0 [0.49, 32.57]
13.2 Prochlorperazine	3	305	Risk Ratio (IV, Random, 95% CI)	1.22 [0.52, 2.89]
13.3 Metoclopramide	1	30	Risk Ratio (IV, Random, 95% CI)	17.0 [1.07, 270.41]
13.4 Chlorpromazine	1	40	Risk Ratio (IV, Random, 95% CI)	7.0 [0.95, 51.80]
14 Paranoia	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
14.1 Prochlorperazine	1	42	Risk Ratio (IV, Random, 95% CI)	3.0 [0.13, 69.70]
15 Sedation	11	1055	Risk Ratio (IV, Random, 95% CI)	1.33 [1.08, 1.64]
15.1 Domperidone	1	38	Risk Ratio (IV, Random, 95% CI)	1.22 [0.66, 2.25]
15.2 Prochlorperazine	8	947	Risk Ratio (IV, Random, 95% CI)	1.44 [1.18, 1.76]
15.3 Metoclopramide	1	30	Risk Ratio (IV, Random, 95% CI)	0.93 [0.73, 1.18]
15.4 Chlorpromazine	1	40	Risk Ratio (IV, Random, 95% CI)	1.71 [0.85, 3.44]
16 Depression	3	317	Risk Ratio (IV, Random, 95% CI)	0.81 [0.51, 1.28]
16.1 Prochlorperazine	3	317	Risk Ratio (IV, Random, 95% CI)	0.81 [0.51, 1.28]
17 Participant preference	9	799	Risk Ratio (IV, Random, 95% CI)	2.76 [1.88, 4.03]
17.1 Prochlorperazine	7	695	Risk Ratio (IV, Random, 95% CI)	3.24 [2.23, 4.72]
17.2 Metoclopramide	1	64	Risk Ratio (IV, Random, 95% CI)	1.2 [0.61, 2.37]
17.3 Chlorpromazine	1	40	Risk Ratio (IV, Random, 95% CI)	2.0 [0.83, 4.81]
18 Withdrawal for any reason	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
18.1 Prochlorperazine	1	42	Risk Ratio (IV, Random, 95% CI)	3.5 [1.38, 8.89]
19 Withdrawal due to adverse event	6	740	Risk Ratio (IV, Random, 95% CI)	3.16 [1.26, 7.93]
19.1 Domperidone	1	76	Risk Ratio (IV, Random, 95% CI)	3.0 [0.13, 71.40]
19.2 Prochlorperazine	5	664	Risk Ratio (IV, Random, 95% CI)	3.90 [1.25, 12.20]
20 Withdrawal due to lack of efficacy	2	118	Risk Ratio (IV, Random, 95% CI)	0.97 [0.04, 20.93]
20.1 Domperidone	1	76	Risk Ratio (IV, Random, 95% CI)	0.14 [0.01, 2.67]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
20.2 Prochlorperazine	1	42	Risk Ratio (IV, Random, 95% CI)	3.5 [1.38, 8.89]


Analysis 2.1. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 1 Absence of nausea.




Analysis 2.2. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 2 Absence of nausea (subgroup analysis 2).




Analysis 2.3. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 3 Absence of vomiting.




Analysis 2.4. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 4 Absence of vomiting (subgroup analysis 2).




Analysis 2.5. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 5 Absence of nausea and vomiting.




Analysis 2.6. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 6 Absence of nausea and vomiting (subgroup analysis 1).




Analysis 2.7. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 7 Absence of nausea and vomiting (subgroup analysis 2).




Analysis 2.8. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 8 Dizziness.







Analysis 2.9. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 9 Dysphoria.




Analysis 2.10. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 10 Euphoria.







Analysis 2.11. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 11 'Feeling high'




Analysis 2.12. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 12 Hallucinations.





Analysis 2.13. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 13 Postural hypotension.



Study or subgroup	Cannabinoid n/N	Control n/N	Risk Ratio IV, Random, 95% CI	Weight	Risk Ratio IV, Random, 95% CI
-------------------	--------------------	----------------	----------------------------------	--------	----------------------------------

Heterogeneity: Tau²=0.8; Chi²=12.62, df=5(P=0.03); I²=60.38%
 Test for overall effect: Z=1.71(P=0.09)
 Test for subgroup differences: Chi²=5.48, df=1 (P=0.14), I²=45.21%

Favours cannabinoid 0.05 0.2 1 5 20 Favours control

Analysis 2.14. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 14 Paranoia.

Study or subgroup	Cannabinoid n/N	Control n/N	Risk Ratio IV, Random, 95% CI	Weight	Risk Ratio IV, Random, 95% CI
2.14.1 Prochlorperazine					
Lane 1991	1/21	0/21		100%	3[0.13,69.7]
Subtotal (95% CI)	21	21		100%	3[0.13,69.7]


Total events: 1 (Cannabinoid), 0 (Control)
 Heterogeneity: Not applicable
 Test for overall effect: Z=0.68(P=0.49)

Favours cannabinoid 0.05 0.2 1 5 20 Favours control


Analysis 2.15. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 15 Sedation.

Study or subgroup	Cannabinoid n/N	Control n/N	Risk Ratio IV, Random, 95% CI	Weight	Risk Ratio IV, Random, 95% CI
2.15.1 Domperidone					
Pomeroy 1986	11/19	9/19		7.87%	1.22[0.66,2.25]
Subtotal (95% CI)	19	19		7.87%	1.22[0.66,2.25]
Total events: 11 (Cannabinoid), 9 (Control) Heterogeneity: Not applicable Test for overall effect: Z=0.65(P=0.52)					
2.15.2 Prochlorperazine					
Ahmedzai 1983	4/28	1/26		0.93%	3.71[0.44,31.11]
Frytak 1979	29/38	29/41		17.21%	1.08[0.83,1.41]
Herman 1979	96/113	54/113		19.25%	1.78[1.44,2.19]
Johansson 1982	1/26	0/23		0.43%	2.67[0.11,62.42]
Lane 1991	4/21	3/21		2.12%	1.33[0.34,5.24]
Niiranen 1985	2/24	0/24		0.48%	5[0.25,98.96]
Steele 1980	25/53	15/43		10.13%	1.35[0.82,2.22]
Ungerleider 1982	78/172	56/181		16.93%	1.47[1.12,1.92]
Subtotal (95% CI)	475	472		67.49%	1.44[1.18,1.76]
Total events: 239 (Cannabinoid), 158 (Control) Heterogeneity: Tau ² =0.02; Chi ² =10.1, df=7(P=0.18); I ² =30.67% Test for overall effect: Z=3.63(P=0)					
2.15.3 Metoclopramide					
Gralla 1984	13/15	14/15		18.1%	0.93[0.73,1.18]
Subtotal (95% CI)	15	15		18.1%	0.93[0.73,1.18]
Total events: 13 (Cannabinoid), 14 (Control) Heterogeneity: Not applicable					


Favours cannabinoid 0.05 0.2 1 5 20 Favours control




Analysis 2.16. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 16 Depression.




Analysis 2.17. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 17 Participant preference.







Analysis 2.18. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 18 Withdrawal for any reason.




Analysis 2.19. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 19 Withdrawal due to adverse event.






Analysis 2.20. Comparison 2 Cannabinoid versus other anti-emetic agent, Outcome 20 Withdrawal due to lack of efficacy.




Comparison 3. Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Absence of nausea	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
2 Absence of vomiting	2	89	Risk Ratio (IV, Random, 95% CI)	1.47 [0.69, 3.13]
3 Absence of nausea and vomiting	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
4 Depression	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
5 Dizziness	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
6 Dysphoria	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
7 Paranoia	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
8 Sedation	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
9 Withdrawal for any reason	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only
10 Withdrawal due to adverse event	2	105	Risk Ratio (IV, Random, 95% CI)	6.97 [0.88, 55.19]
11 Withdrawal due to lack of efficacy	1		Risk Ratio (IV, Random, 95% CI)	Subtotals only


Analysis 3.1. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 1 Absence of nausea.




Analysis 3.2. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 2 Absence of vomiting.




Analysis 3.3. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 3 Absence of nausea and vomiting.




Analysis 3.4. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 4 Depression.




Analysis 3.5. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 5 Dizziness.




Analysis 3.6. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 6 Dysphoria.




Analysis 3.7. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 7 Paranoia.




Analysis 3.8. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 8 Sedation.




Analysis 3.9. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 9 Withdrawal for any reason.



Analysis 3.10. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 10 Withdrawal due to adverse event.



Analysis 3.11. Comparison 3 Cannabinoid plus other antiemetic agent versus other antiemetic monotherapy, Outcome 11 Withdrawal due to lack of efficacy.



APPENDICES

Appendix 1. CENTRAL search strategy

- #1 MeSH descriptor: [Antineoplastic Agents] explode all trees
- #2 MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] explode all trees
- #3 chemotherap*
- #4 #1 or #2 or #3

#5 MeSH descriptor: [Nausea] explode all trees
#6 MeSH descriptor: [Vomiting] explode all trees
#7 nause* or vomit*
#8 emesis* or emetic* or antiemetic* or emetogenic*
#9 #5 or #6 or #7 or #8
#10 MeSH descriptor: [Cannabinoids] explode all trees
#11 MeSH descriptor: [Cannabis] explode all trees
#12 cannab*
#13 dronabinol
#14 nabilone
#15 tetrahydrocannabinol
#16 cesamet
#17 delta-9-THC
#18 delta-9-tetrahydrocannabinol
#19 marinol
#20 #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19
#21 #4 and #9 and #20

Appendix 2. MEDLINE search strategy

1 exp Antineoplastic Agents/
2 exp Antineoplastic Combined Chemotherapy Protocols/
3 chemotherap*.mp.
4 1 or 2 or 3
5 exp Nausea/
6 exp Vomiting/
7 (nause* or vomit*).mp.
8 (emesis* or emetic* or antiemetic* or emetogenic*).mp.
9 5 or 6 or 7 or 8
10 exp Cannabinoids/
11 exp Cannabis/
12 cannab*.mp.
13 marinol.mp.
14 dronabinol.mp.
15 nabilone.mp.
16 tetrahydrocannabinol.mp.
17 cesamet.mp.
18 delta-9-THC.mp.
19 delta-9-tetrahydrocannabinol.mp.
20 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
21 randomized controlled trial.pt.
22 controlled clinical trial.pt.
23 randomized.ab.
24 placebo.ab.
25 drug therapy.fs.
26 randomly.ab.
27 trial.ab.
28 groups.ab.
29 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30 4 and 9 and 20 and 29

Key: mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier

Appendix 3. EMBASE search strategy

1 exp chemotherapy/
2 exp antineoplastic agent/
3 chemotherap*.mp.
4 1 and 2 and 3
5 exp "nausea and vomiting"/
6 (nause* or vomit*).mp.
7 (emesis* or emetic* or antiemetic* or emetogenic*).mp.

8 5 or 6 or 7
 9 exp cannabinoid/
 10 cannabis/
 11 cannab*.mp.
 12 marinol.mp.
 13 dronabinol.mp.
 14 nabilone.mp.
 15 tetrahydrocannabinol.mp.
 16 cesamet.mp.
 17 delta-9-THC.mp.
 18 delta-9-tetrahydrocannabinol.mp.
 19 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
 20 4 and 8 and 19
 21 crossover procedure/
 22 double-blind procedure/
 23 randomized controlled trial/
 24 single-blind procedure/
 25 random*.mp.
 26 factorial*.mp.
 27 (crossover* or cross over* or cross-over*).mp.
 28 placebo*.mp.
 29 (double* adj blind*).mp.
 30 (singl* adj blind*).mp.
 31 assign*.mp.
 32 allocat*.mp.
 33 volunteer*.mp.
 34 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33
 35 20 and 34

Key: [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

Appendix 4. PsycInfo search strategy

1 antineoplastic drugs/
 2 chemotherapy/
 3 chemotherap*.mp.
 4 1 or 2 or 3
 5 nausea/
 6 vomiting/
 7 nause*.mp.
 8 vomit*.mp.
 9 (emesis or emetic* or antiemetic* or emetogenic*).mp
 10 5 or 6 or 7 or 8 or 9
 11 exp cannabinoids/
 12 exp cannabis/
 13 cannab*.mp.
 14 marinol.mp.
 15 dronabinol.mp.
 16 nabilone.mp.
 17 tetrahydrocannabinol.mp.
 18 cesamet.mp.
 19 delta-9-THC.mp.
 20 delta-9-tetrahydrocannabinol.mp.
 21 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
 22 4 and 10 and 21

key: [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures]

Appendix 5. LILACS search strategy

((MH:D02.455.848.090\$ OR MH:B01.650.940.800.575.100.175.500 OR cannab\$ OR marinol OR dronabinol OR nabilone OR tetrahydrocannabinol OR cesamet OR delta-9-THC OR delta-9-tetrahydrocannabinol) AND (MH:nausea or MH:vomiting OR MH:emetics OR

MH:antiemetics OR nausea\$ OR vomit\$ OR emesis OR emetic\$ OR emetogenic\$ OR antiemetic\$) AND (MH:D27.505.954.248\$ OR MH:E02.183.750.500 OR MH:E02319.077.500 OR MH:E02.319.310.037 OR chemotherap\$))

CONTRIBUTIONS OF AUTHORS

- Lesley Smith: write protocol, screened studies for inclusion, extracted and analysed data, write final review.
- Fredric Azariah: screened searches, screened studies for inclusion, extracted data, contributed to drafts of the review.
- Verna Lavender: classified chemotherapy regimens, assessed nausea and vomiting measurements, contributed to drafts of the review.
- Nicola Stoner: classified chemotherapy regimens, assessed nausea and vomiting measurements, contributed to drafts of the review.
- Silvana Bettiol: screened searches, screened studies for inclusion, extracted data, contributed to drafts of the review.

DECLARATIONS OF INTEREST

The authors have no conflicts of interest.

SOURCES OF SUPPORT

Internal sources

- Cochrane, UK.
Gynaecological Cancer Review Group

External sources

- No sources of support supplied

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Based on peer review feedback of a draft of the review and inclusion of clinical experts on the review team, we made a number of post-protocol amendments.

'Types of Participants' have changed from "*people*" to "*Adults aged 18 years and over*".

We removed the plan for a subgroup analysis "*by emetic potential of the chemotherapy agent, high versus low emetogenic potential*" and added a new subgroup analysis "*by history of exposure to chemotherapy, chemotherapy naive versus prior chemotherapy treatment*".

The primary outcomes we stated in the protocol are listed in the bullet points below. However, we were unable to analyse data for frequency and severity of nausea or vomiting (or both) due to use of non-valid and reliable measures, and inappropriate analysis of results reported in the primary studies. We focused on the proportion of people with cancer with complete absence of nausea or vomiting or both in common with other systematic reviews of treatments for nausea and vomiting.

- Absence of episodes of nausea and vomiting.
- Frequency of nausea and vomiting.
- Severity of nausea.

We also stated that we would only extract data for the outcome 'participant preference' for the first cross-over period only (erroneously), and, due to none of the trials reporting this, we extracted responses for the entire study period.

We added three additional adverse effects as secondary outcomes: focal dystonia, extrapyramidal effects and oculogyric crisis.

We did not contact pharmaceutical companies for data on file.

Methods for future updates

Data extraction and management

For continuous outcomes (severity of nausea measured using a validated symptom scale), we will extract the final value and standard deviation of the outcome of interest and the number of participants assessed in each treatment arm at the end of follow-up in order to estimate the mean difference between treatment arms (or standardised mean difference if measured on different scales) and its standard error.

Data for frequency of nausea or vomiting, or both, may be reported in a number of ways. For data presented as counts (number of nausea or vomiting (or both) episodes), we will extract the number of events and person-time at risk, if presented, in order to calculate a nausea and vomiting rate per treatment group. For data presented as continuous data, we will extract the mean number of events (nausea or

vomiting (or both) episodes) in each treatment group. For data presented as categorical data (number of participants who experience at least five events), we will proceed as described above for dichotomous data.

Data collection and analysis

If the results are statistically significant, we will calculate the number needed to treat for an additional beneficial outcome (NNTB) or additional harmful outcome (NNTH). For continuous outcomes, we will calculate the difference in means between treatment arms at the end of follow-up. We will consider the magnitude of the effect of an intervention as at least moderate if the 'effect size' is superior to 0.5 (Cohen 1988). For outcomes reported as rates, we will calculate the rate ratio.

Wherever the data are missing or only imputed data are reported, we will contact the trial authors and request the data on the outcomes only among the participants who were assessed.

Where the trials have multiple treatment groups, we will divide the 'shared' comparison group into the number of treatment groups and treat comparisons between each treatment group and the split comparison group as independent comparisons.

Unit of analysis

In future updates it may be possible to:

- obtain data from study authors for each treatment period or summary statistics of the degree of agreement between each person's responses, or both;
- adjust the analyses for the dichotomous outcomes to take into account the paired data.

INDEX TERMS

Medical Subject Headings (MeSH)

Antiemetics [adverse effects] [*therapeutic use]; Antineoplastic Agents [adverse effects]; Cannabinoids [adverse effects] [*therapeutic use]; Chlorpromazine [adverse effects] [therapeutic use]; Dizziness [chemically induced]; Domperidone [adverse effects] [therapeutic use]; Euphoria; Metoclopramide [adverse effects] [therapeutic use]; Nausea [chemically induced] [*drug therapy]; Neoplasms [*drug therapy]; Prochlorperazine [adverse effects] [therapeutic use]; Randomized Controlled Trials as Topic; Vomiting [chemically induced] [*drug therapy]

MeSH check words

Adult; Humans